Professor Christopher Sweeney
Director, SAiGENCI
South Australian Immunogenomics Cancer Institute
Faculty of Health and Medical Sciences
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
Professor Christoper Sweeney MBBS is a Medical Oncologist and the inaugural Director of the South Australian immunoGENomics Cancer Institute (SAiGENCI) at the University of Adelaide.
Professor Sweeney received his medical degree from the University of Adelaide, South Australia in 1992 and completed an internship at the Royal Adelaide Hospital. He did his residency in internal medicine at Gundersen Lutheran Medical Center (Wisconsin, USA) and a fellowship in Hematology/Oncology at Indiana University Medical Center (Indiana, USA), where he was later appointed Associate Director for Clinical Research for the Simon Cancer Center. Professor Sweeney joined the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute and Harvard Medical School (Massachusetts, USA) in 2009.
Professor Sweeney's primary research interest is drug discovery and development. His academic focus is management of genitourinary malignancies, with a focus on prostate and testicular cancer. Professor Sweeney is a highly active contributor to his field, having served on the Editorial Board for ASCOs Journal of Clinical Oncology and the Program and Cancer Education Committees of the American Society of Clinical Oncology. He has received peer reviewed funding from the National Institutes of Health and the Department of Defense. Professor Sweeney is also a member of the Scientific Advisory Boards of biotech companies in the United States and Australia.
He is a member of the American Society of Clinical Oncology, the Eastern Cooperative Oncology Group-ACRIN, Alliance and the American Association for Cancer Research.
Professor Sweeney is a clinician researcher with a translational approach focussed on drug discovery and development. His primary research interest is on the management of genitourinary malignancies, in particular prostate and testicular cancer.
Professor Sweeney has over 25 years of experience in hematology and oncology and leading clinical trials as well preclinical drug discovery and translational research. He has either led or contributed to over 300 peer-reviewed original research publications as well as more than 50 peer-reviewed teaching papers and more than 25 review articles and book chapters. He has been a first or senior author on high-ranking journals such as the New England Journal of Medicine, Lancet, Nature and Nature Medicine, Journal of Clinical Oncology and Annals of Oncology. He has led several clinical trials (in the US, Australia, Canada, UK and Ireland) that have changed and/or informed the care of men with prostate and bladder cancer and germ cell tumours. He is also Principal Investigator of the ICECaP international collaboration that has led to new endpoints for prostate cancer trials that have been accepted by regulatory agencies in USA and Europe (icecap.movember.com).
As a result of 20 years of research, Professor Sweeney developed a novel prostate cancer therapy targeting nuclear factor kappa B in the laboratory, dimethylaminoparthenolide (DMAPT) and also identified tristetraprolin (TTP) as regulator of NF-kappa B and a biomarker of lethal prostate cancer. This discovery forms the basis of Professor Sweeney’s ongoing investigational drug development. The Sweeney group will continue exploring the role of NF-κB and its impact on prostate cancer progression and resistance to therapy with specific interest on phenotypic plasticity.
Other projects planned include the use of DMAPT with Radioligand Therapy (RLT), which targets the prostate specific membrane antigen (PSMA) which is a recent development in the treatment of metastatic castration resistant prostate cancer. The aim is to investigate the ability of pro-oxidative properties of DMAPT to increase efficacy of RLT in prostate cancer and understand the underlying mechanisms which has led to our previous observations that DMAPT enhanced anti-cancer activity of radiation while also protecting normal tissue from radiation.
Professor Sweeney is also overseeing a large collaborative project to develop an integrated cancer analytics repository which will create a globally accessible comprehensive and integrated data asset of immense clinical value combining clinical, molecular and imaging data from patients with mHSPC. Data from ~2000 patients from clinical trials already exist and will be utilised in the first instance. (Once the infrastructure is established, the team will look to expand this model to other cancers). The repository will link clinical, radiological, biological and social determinant data to better understand the causes of cancer, drivers of cancer progression and to identify new targets for the development of new cancer drugs.
The Sweeney group are also investigating MYBL2, a MYB family transcription factor, a physiological regulator of cell cycle progression, cell survival and cell differentiation. It is frequently found to be dysregulated in cancer. Professor Sweeney’s group will investigate strategies to block the docking of MYBL2 to the MuvB core to prevent upregulation of the downstream MYBL2-MuvB transcriptional network. The aim of this project is to investigate and validate candidate compounds from a virtual screening platform as novel MYBL2 inhibitors that can be used in treatment of aggressive PCa.
-
Appointments
Date Position Institution name 2022 - ongoing Director University of Adelaide 2018 - 2022 Professor Harvard Medical School 2017 - ongoing Associate Member Massachusetts Institute of Technology 2013 - ongoing Honorary Associate University of Sydney 2010 - 2018 Associate Professor Harvard Medical School 2010 - 2010 Lecturer in Medicine Harvard Medical School 2009 - ongoing Visiting Professor University of Adelaide 2008 - 2009 Professor University of Adelaide 2007 - 2007 Associate Professor Indiana University Hospital 2001 - 2023 Assistant Professor Indiana University Hospital -
Education
Date Institution name Country Title 2018 Harvard University United States Masters of Arts (MA) 1993 University of Adelaide Australia Bachelor of Medicine, Bachelor of Surgery (MBBS) -
Postgraduate Training
Date Title Institution Country 1997 - 2000 Fellow Indiana University Hospital United States 1994 - 1997 Resident Gundersen Lutheran Hospital United States 1994 - 1994 Physician Trainee Royal Adelaide Hospital Australia 1993 - 1993 Internship Royal Adelaide Hospital Australia -
Research Interests
-
Journals
Year Citation 2024 Sutera, P., Shetty, A. C., Song, Y., Hodges, T., Hoang, T., Rana, Z., . . . Tran, P. T. (2024). Identification of a Predictive Genomic Biomarker for Prostate-directed Therapy in Synchronous Low-volume Metastatic Castration-sensitive Prostate Cancer. European urology oncology, 7(2), 241-247.
2024 Rosen, D. B., Ghosh, A., Niemierko, A., Beard, C. J., Ravi, P., Tewari, A., . . . Kamran, S. C. (2024). Clinical Outcomes of De Novo Versus Relapsed Early Metastatic Testicular Seminoma Treated With Contemporary Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 118(3), 706-711.
Scopus12024 Sweeney, C. J., Hainsworth, J. D., Bose, R., Burris, H. A., Kurzrock, R., Swanton, C., . . . Meric-Bernstam, F. (2024). MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab 1 Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2–Altered Advanced Solid Tumors. Journal of Clinical Oncology, 42(3), 258-265.
Scopus2 Europe PMC72024 Xie, W., Ravi, P., Buyse, M., Halabi, S., Kantoff, P., Sartor, O., . . . Sweeney, C. J. (2024). Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer. Annals of Oncology, 35(3), 285-292.
2024 Halabi, S., Roy, A., Rydzewska, L., Guo, S., Godolphin, P., Hussain, M., . . . Sweeney, C. (2024). Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer. Journal of Clinical Oncology, 42(9), 1044-1054.
Scopus1 Europe PMC12024 Kwak, L., Ravi, P., Armstrong, J. G., Beckendorf, V., Chin, J. L., D'Amico, A. V., . . . Sweeney, C. J. (2024). Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized Trials.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2300762.
2024 Bührer, E., D'Haese, D., Daugaard, G., de Wit, R., Albany, C., Tryakin, A., . . . Beyer, J. (2024). Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium. European Journal of Cancer, 202, 114042.
2024 Choudhury, A. D., Kwak, L., Cheung, A., Allaire, K. M., Marquez, J., Yang, D. D., . . . Fong, L. (2024). Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer.. Cancer immunology research, OF1-OF15.
Europe PMC22024 Hamid, A. A., Sweeney, C. J., Hovens, C., Corcoran, N., & Azad, A. A. (2024). Precision medicine for prostate cancer: An international perspective. Urologic Oncology: Seminars and Original Investigations.
2023 Lauritsen, J., Sauvé, N., Tryakin, A., Jiang, D. M., Huddart, R., Heng, D. Y. C., . . . Daugaard, G. (2023). Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database. British Journal of Cancer, 129(11), 1759-1765.
2023 Parry, M. A., Grist, E., Mendes, L., Dutey-Magni, P., Sachdeva, A., Brawley, C., . . . Attard, G. (2023). Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial.. Res Sq.
2023 Mahal, B. A., Kwak, L., Xie, W., Eastham, J. A., James, N. D., Sandler, H. M., . . . D'Amico, A. V. (2023). Mortality Risk for Docetaxel-Treated, High-Grade Prostate Cancer with Low PSA Levels: A Meta-Analysis. JAMA Network Open, 6(11), E2340787.
Scopus12023 Rana, H. Q., Stopfer, J. E., Weitz, M., Kipnis, L., Koeller, D. R., Culver, S., . . . Taplin, M. E. (2023). Pretest Video Education Versus Genetic Counseling for Patients with Prostate Cancer: ProGen, A Multisite Randomized Controlled Trial. JCO Oncology Practice, 19(11), 1069-1079.
2023 Sweeney, C. J., Martin, A. J., Stockler, M. R., Begbie, S., Cheung, L., Chi, K. N., . . . ENZAMET trial investigators and Australian and New Zealand Urogenital and Prostate Cancer Trials Group. (2023). Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.. Lancet Oncol, 24(4), 323-334.
Scopus26 WoS19 Europe PMC122023 Gil da Costa, R. M., Levesque, C., Bianchi-Frias, D., Chatterjee, P., Lam, H. M., Santos, C., . . . Nelson, P. S. (2023). Pharmacological NF-κB inhibition decreases cisplatin chemoresistance in muscle-invasive bladder cancer and reduces cisplatin-induced toxicities.. Molecular Oncology, 17(12), 2709-2727.
Scopus1 WoS1 Europe PMC22023 Ravi, P., Wang, V., Fichorova, R. N., McGregor, B., Wei, X. X., Basaria, S., & Sweeney, C. J. (2023). IGF-1 axis changes with ADT and docetaxel in metastatic prostate cancer. ENDOCRINE-RELATED CANCER, 30(11), 8 pages.
2023 Fankhauser, C. D., Jandari, A., Collette, L., Tandstad, T., Jiang, D. M., De Giorgi, U., . . . Gillessen, S. (2023). Prechemotherapy Not Preorchiectomy Serum Tumor Markers Accurately Identify International Germ Cell Cancer Collaborative Group Prognostic Groups in Nonseminoma.. European urology open science, 56, 25-28.
2023 Quinn, Z., Leiby, B., Sonpavde, G., Choudhury, A. D., Sweeney, C., Einstein, D., . . . Kelly, W. K. (2023). Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer. Clinical Cancer Research, 29(1), 50-59.
Scopus7 Europe PMC32023 Gillessen, S., Bossi, A., Davis, I. D., de Bono, J., Fizazi, K., James, N. D., . . . Suzuki, H. (2023). Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. European Urology, 83(3), 267-293.
Scopus38 WoS13 Europe PMC172023 Matsubara, N., de Bono, J., Sweeney, C., Chi, K. N., Olmos, D., Sandhu, S., . . . Sternberg, C. N. (2023). Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 21(2), 230-237.e1.
2023 Gillessen, S., Bossi, A., Davis, I. D., de Bono, J., Fizazi, K., James, N. D., . . . Suzuki, H. (2023). Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. European Journal of Cancer, 185, 178-215.
Scopus29 WoS19 Europe PMC152023 Antonelli, L., Ardizzone, D., Ravi, P., Bagrodia, A., Mego, M., Daneshmand, S., . . . Fankhauser, C. D. (2023). Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study. European Journal of Cancer, 182, 144-154.
Scopus1 Europe PMC12023 Riaz, I. B., Naqvi, S. A. A., He, H., Asghar, N., Siddiqi, R., Liu, H., . . . Bryce, A. H. (2023). First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer: A Living Systematic Review and Network Meta-analysis.. JAMA oncology, 9(5), 635-645.
Scopus17 WoS17 Europe PMC92023 Pomykala, K. L., Hadaschik, B. A., Sartor, O., Gillessen, S., Sweeney, C. J., Maughan, T., . . . Herrmann, K. (2023). Next Generation Radiotheranostics Promoting Precision Medicine.. Annals of oncology : official journal of the European Society for Medical Oncology, 34(6), 507-519.
Scopus9 WoS1 Europe PMC72023 Weiner, A. B., Liu, Y., Hakansson, A., Zhao, X., Proudfoot, J. A., Ho, J., . . . Schaeffer, E. M. (2023). A novel prostate cancer subtyping classifier based on luminal and basal phenotypes. Cancer, 129(14), 2169-2178.
Scopus3 Europe PMC42023 Beije, N., Abida, W., Antonarakis, E. S., Castro, E., de Wit, R., Fizazi, K., . . . de Bono, J. S. (2023). PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues.. European urology, 84(3), S0302-2838(23)02716-1.
Scopus8 Europe PMC52023 Sutera, P. A., Shetty, A. C., Hakansson, A., Van der Eecken, K., Song, Y., Liu, Y., . . . Ost, P. (2023). Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer. Annals of Oncology, 34(7), 605-614.
Scopus3 WoS1 Europe PMC12023 Sutera, P., Song, Y., Van der Eecken, K., Shetty, A. C., English, K., Hodges, T., . . . Tran, P. T. (2023). Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer. European Urology, 84(6), 531-535.
Scopus3 WoS1 Europe PMC22023 Sweeney, C. J., Percent, I. J., Babu, S., Cultrera, J. L., Mehlhaff, B. A., Goodman, O. B., . . . Bendell, J. C. (2023). Supplementary Data from Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer.
2023 Sweeney, C. J., Percent, I. J., Babu, S., Cultrera, J. L., Mehlhaff, B. A., Goodman, O. B., . . . Bendell, J. C. (2023). Supplementary Figure from Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer.
2023 Sweeney, C. J., Percent, I. J., Babu, S., Cultrera, J. L., Mehlhaff, B. A., Goodman, O. B., . . . Bendell, J. C. (2023). Data from Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer.
2023 Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Data from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.
2023 Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Figure S2 from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.
2023 Friedman, C. F., Hainsworth, J. D., Kurzrock, R., Spigel, D. R., Burris, H. A., Sweeney, C. J., . . . Swanton, C. (2023). Supplementary Figure from Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study.
2023 Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Figure S1 from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.
2023 Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Figure S3 from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.
2023 Friedman, C. F., Hainsworth, J. D., Kurzrock, R., Spigel, D. R., Burris, H. A., Sweeney, C. J., . . . Swanton, C. (2023). Supplementary Figure from Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study.
2023 Sweeney, C. J., Percent, I. J., Babu, S., Cultrera, J. L., Mehlhaff, B. A., Goodman, O. B., . . . Bendell, J. C. (2023). Supplementary Data from Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer.
2023 Sweeney, C. J., Percent, I. J., Babu, S., Cultrera, J. L., Mehlhaff, B. A., Goodman, O. B., . . . Bendell, J. C. (2023). Data from Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer.
2023 Quinn, Z., Leiby, B., Sonpavde, G., Choudhury, A. D., Sweeney, C., Einstein, D., . . . Kelly, W. K. (2023). Data from Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer.
2023 Sweeney, C. J., Percent, I. J., Babu, S., Cultrera, J. L., Mehlhaff, B. A., Goodman, O. B., . . . Bendell, J. C. (2023). Supplementary Figure from Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer.
2023 Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Table S2 from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.
2023 Quinn, Z., Leiby, B., Sonpavde, G., Choudhury, A. D., Sweeney, C., Einstein, D., . . . Kelly, W. K. (2023). Supplementary Figure S1 from Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer.
2023 Quinn, Z., Leiby, B., Sonpavde, G., Choudhury, A. D., Sweeney, C., Einstein, D., . . . Kelly, W. K. (2023). Data from Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer.
2023 Friedman, C. F., Hainsworth, J. D., Kurzrock, R., Spigel, D. R., Burris, H. A., Sweeney, C. J., . . . Swanton, C. (2023). Supplementary Data from Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study.
2023 Friedman, C. F., Hainsworth, J. D., Kurzrock, R., Spigel, D. R., Burris, H. A., Sweeney, C. J., . . . Swanton, C. (2023). Data from Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study.
2023 Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Data from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.
2023 Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Table S2 from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.
2023 Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Table S1 from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.
2023 Sweeney, C. J., Percent, I. J., Babu, S., Cultrera, J. L., Mehlhaff, B. A., Goodman, O. B., . . . Bendell, J. C. (2023). Supplementary Figure from Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer.
2023 Quinn, Z., Leiby, B., Sonpavde, G., Choudhury, A. D., Sweeney, C., Einstein, D., . . . Kelly, W. K. (2023). Supplementary Figure S1 from Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer.
2023 Sweeney, C. J., Percent, I. J., Babu, S., Cultrera, J. L., Mehlhaff, B. A., Goodman, O. B., . . . Bendell, J. C. (2023). Supplementary Figure from Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer.
2023 Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Figure S1 from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.
2023 Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Figure S4 from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.
2023 Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Figure S2 from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.
2023 Friedman, C. F., Hainsworth, J. D., Kurzrock, R., Spigel, D. R., Burris, H. A., Sweeney, C. J., . . . Swanton, C. (2023). Supplementary Data from Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study.
2023 Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Table S1 from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.
2023 Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Figure S4 from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.
2023 Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Figure S3 from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.
2023 Friedman, C. F., Hainsworth, J. D., Kurzrock, R., Spigel, D. R., Burris, H. A., Sweeney, C. J., . . . Swanton, C. (2023). Data from Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study.
2023 Hamid, A. A., Sayegh, N., Tombal, B., Hussain, M., Sweeney, C. J., Graff, J. N., & Agarwal, N. (2023). Metastatic Hormone-Sensitive Prostate Cancer: Toward an Era of Adaptive and Personalized Treatment.. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 43(43), e390166.
Europe PMC32023 Jackson-Spence, F., Young, M., Sweeney, C., & Powles, T. (2023). Top advances of the year: Genitourinary cancer. Cancer, 129(17), 2603-2609.
Scopus2 WoS1 Europe PMC12023 Vale, C. L., Fisher, D. J., Godolphin, P. J., Rydzewska, L. H., Boher, J. -M., Burdett, S., . . . STOPCAP Collaboration. (2023). Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials.. The Lancet. Oncology, 24(7), 783-797.
Scopus11 WoS10 Europe PMC52022 Friedman, C. F., Hainsworth, J. D., Kurzrock, R., Spigel, D. R., Burris, H. A., Sweeney, C. J., . . . Swanton, C. (2022). Atezolizumab Treatment of Tumors With High Tumor Mutational Burden From MyPathway, a Multicenter, Open-label, Phase 2a Multiple Basket Study.. Cancer Discov, 12(3), 654-669.
Scopus36 WoS28 Europe PMC242022 Buyse, M., Saad, E. D., Burzykowski, T., Regan, M. M., & Sweeney, C. S. (2022). Surrogacy Beyond Prognosis:The Importance of “Trial-Level” Surrogacy. Oncologist, 27(4), 266-271.
Scopus21 Europe PMC92022 Weiner, A. B., Siebert, A. L., Fenton, S. E., Abida, W., Agarwal, N., Davis, I. D., . . . Sweeney, C. J. (2022). First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the Literature.. European urology oncology, 5(4), 377-387.
Scopus4 WoS3 Europe PMC22022 Powles, T., Yuen, K. C., Gillessen, S., Kadel, E. E., Rathkopf, D., Matsubara, N., . . . Sweeney, C. J. (2022). Re: Atezolizumab with Enzalutamide versus Enzalutamide Alone in Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase 3 Trial. Journal of Urology, 208(1), 214-215.
2022 Terbuch, A., Posch, F., Bauernhofer, T., Jost, P. J., Partl, R., Stranzl-Lawatsch, H., . . . Gillessen, S. (2022). Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 113(4), 825-832.
Scopus2 WoS22022 Morgans, A. K., Chen, Y. -H., Jarrard, D. F., Carducci, M., Liu, G., Eisenberger, M., . . . ECOG-ACRIN E3805 Investigators. (2022). Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805.. The Prostate, 82(12), 1176-1185.
Scopus2 WoS12022 Riaz, I. B., & Sweeney, C. J. (2022). The role of chemotherapy in metastatic prostate cancer. Current opinion in urology, 32(3), 292-301.
Scopus4 WoS4 Europe PMC32022 Yoshikawa, Y., Stopsack, K. H., Wang, X. V., Chen, Y. H., Mazzu, Y. Z., Burton, F., . . . Sweeney, C. J. (2022). Increased MYBL2 expression in aggressive hormone-sensitive prostate cancer. Molecular Oncology, 16(22), 3909-4063.
Scopus3 WoS1 Europe PMC32022 Baca, S. C., Singler, C., Zacharia, S., Seo, J. H., Morova, T., Hach, F., . . . Freedman, M. L. (2022). Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulation. Nature Genetics, 54(9), 1364-1375.
Scopus14 WoS11 Europe PMC182022 Grist, E., Friedrich, S., Brawley, C., Mendes, L., Parry, M., Ali, A., . . . Attard, G. (2022). Accumulation of copy number alterations and clinical progression across advanced prostate cancer. Genome Medicine, 14(1), 15 pages.
Scopus7 WoS3 Europe PMC72022 Vogl, U. M., Beer, T. M., Davis, I. D., Shore, N. D., Sweeney, C. J., Ost, P., . . . Gillessen, S. (2022). Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. European Journal of Cancer, 160, 24-60.
Scopus13 WoS10 Europe PMC62022 Martinez Chanza, N., Bernard, B., Barthelemy, P., Accarain, A., Paesmans, M., Desmyter, L., . . . Sweeney, C. J. (2022). Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer. Prostate Cancer and Prostatic Diseases, 25(2), 199-207.
Scopus4 WoS2 Europe PMC32022 Powles, T., Yuen, K. C., Gillessen, S., Kadel, E. E., Rathkopf, D., Matsubara, N., . . . Sweeney, C. J. (2022). Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial.. Nature medicine, 28(1), 144-153.
Scopus87 WoS65 Europe PMC592022 Brennan, V., Spektor, A., Sweeney, C., Choudhury, A., Rathkopf, D., Pomerantz, M., . . . King, M. (2022). Evaluating the Role of Stereotactic Body Radiation Therapy With Respect to Androgen Receptor Signaling Inhibitors for Oligometastatic Prostate Cancer. Advances in Radiation Oncology, 7(1), 8 pages.
Scopus5 WoS3 Europe PMC22022 Wei, X. X., Kwak, L., Hamid, A., He, M., Sweeney, C., Flanders, S. C., . . . Choudhury, A. D. (2022). Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: experience at Dana Farber and in the PROCEED Registry.. Prostate Cancer Prostatic Dis, 25(2), 314-319.
Scopus5 WoS3 Europe PMC32022 Turco, F., Armstrong, A., Attard, G., Beer, T. M., Beltran, H., Bjartell, A., . . . Omlin, A. (2022). What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 82(1), 6-11.
Scopus4 WoS5 Europe PMC42022 Sweeney, C. J., Percent, I. J., Babu, S., Cultrera, J. L., Mehlhaff, B. A., Goodman, O. B., . . . Bendell, J. C. (2022). Phase 1b/2 Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research, 28(11), 2237-2247.
Scopus14 WoS7 Europe PMC92022 Stockler, M. R., Martin, A. J., Dhillon, H. M., Davis, I. D., & Sweeney, C. J. (2022). Reply to L. Marandino et al.. Journal of Clinical Oncology, 40(19), 2176-2177.
Scopus1 WoS12022 Hussain, M., Carducci, M. A., Clarke, N., Fenton, S. E., Fizazi, K., Gillessen, S., . . . Sweeney, C. (2022). Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 69(26), JCO2200208.
Scopus10 WoS7 Europe PMC52022 Gillessen, S., Armstrong, A., Attard, G., Beer, T. M., Beltran, H., Bjartell, A., . . . Omlin, A. (2022). Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 82(1), 115-141.
Scopus46 WoS33 Europe PMC282022 Turco, F., Armstrong, A., Attard, G., Beer, T. M., Beltran, H., Bjartell, A., . . . Omlin, A. (2022). Corrigendum to “What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021” [Eur Urol 2022] (European Urology, (S0302283822016505), (10.1016/j.eururo.2022.02.010)). European Urology, 82(1), e18-e19.
2021 Hamid, A. A., Huang, H. C., Wang, V., Chen, Y. H., Feng, F., Den, R., . . . Sweeney, C. J. (2021). Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial. Annals of Oncology, 32(9), 1157-1166.
Scopus35 WoS30 Europe PMC242021 Sweeney, C., Bracarda, S., Sternberg, C. N., Chi, K. N., Olmos, D., Sandhu, S., . . . de Bono, J. S. (2021). Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. The Lancet, 398(10295), 131-142.
Scopus159 WoS66 Europe PMC1132021 Francini, E., Montagnani, F., Nuzzo, P. V., Gonzalez-Velez, M., Alimohamed, N. S., Rosellini, P., . . . Heng, D. Y. C. (2021). Association of Concomitant Bone Resorption Inhibitors with Overall Survival among Patients with Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate with Prednisone as First-Line Therapy. JAMA Network Open, 4(7), 13 pages.
Scopus10 WoS9 Europe PMC102021 Javle, M., Borad, M. J., Azad, N. S., Kurzrock, R., Abou-Alfa, G. K., George, B., . . . Burris, H. (2021). Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study.. The Lancet. Oncology, 22(9), 1290-1300.
Scopus180 WoS118 Europe PMC1032021 Francini, E., Ou, F. S., Rhoades, J., Wolfe, E. G., O’connor, E. P., Ha, G., . . . Choudhury, A. D. (2021). Circulating cell-free dna as biomarker of taxane resistance in metastatic castration-resistant prostate cancer. Cancers, 13(16), 12 pages.
Scopus1 Europe PMC12021 Sweeney, C. J., Martin, A. J., Stockler, M. R., Begbie, S., Chi, K. N., Chowdhury, S., . . . ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). (2021). Overall survival of men with metachronous metastatic hormone-sensitive prostate cancer treated with enzalutamide and androgen deprivation therapy. European Urology, 80(3), 275-279.
Scopus25 WoS17 Europe PMC152021 Stockler, M. R., Martin, A. J., Davis, I. D., Dhillon, H. M., Begbie, S. D., Chi, K. N., . . . ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). (2021). Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP. Journal of Clinical Oncology, 40(8), 837-846.
Scopus18 WoS16 Europe PMC192021 Sweeney, C. J., Martin, A. J., Stockler, M. R., Begbie, S., Chi, K. N., Chowdhury, S., . . . Davis, I. D. (2021). Re: Overall Survival of Men with Metachronous Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. JOURNAL OF UROLOGY, 206(6), 1519-1520. 2021 Fankhauser, C. D., Tran, B., Pedregal, M., Ruiz-Morales, J. M., Gonzalez-Billalabeitia, E., Patrikidou, A., . . . Connors, J. M. (2021). A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy. European Urology Focus, 7(5), 1130-1136.
Scopus13 WoS11 Europe PMC52021 McGregor, B., Zhang, L., Gray, K. P., Shaw, G., Evan, C., Francini, E., & Sweeney, C. (2021). Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases. Prostate Cancer and Prostatic Diseases, 24(2), 341-348.
Scopus8 WoS6 Europe PMC72021 Beyer, J., Collette, L., Sauvé, N., Daugaard, G., Feldman, D. R., Tandstad, T., . . . International Germ Cell Cancer Classification Update Consortium. (2021). Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium.. J Clin Oncol, 39(14), 1553-1562.
Scopus84 WoS52 Europe PMC442021 Morel, K. L., Sheahan, A. V., Burkhart, D. L., Baca, S. C., Boufaied, N., Liu, Y., . . . Ellis, L. (2021). EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nature Cancer, 2(4), 444-456.
Scopus110 WoS90 Europe PMC832021 Gillessen, S., Sauvé, N., Collette, L., Daugaard, G., de Wit, R., Albany, C., . . . International Germ Cell Cancer Classification Update Consortium. (2021). Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium.. J Clin Oncol, 39(14), 1563-1574.
Scopus97 WoS71 Europe PMC602021 Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2021). NF-κB blockade with oral administration of dimethylaminoparthenolide, delays prostate cancer resistance to androgen receptor inhibition and inhibits AR variants. Mol Cancer Res, 19(7), 1137-1145.
Scopus7 WoS5 Europe PMC52021 Hofmann, M. R., Hussain, M., Dehm, S. M., Beltran, H., Wyatt, A. W., Halabi, S., . . . Sharifi, N. (2021). Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary. Urology, 155, 165-171.
Scopus6 WoS8 Europe PMC62021 Feng, F. Y., Huang, H. C., Spratt, D. E., Zhao, S., Sandler, H. M., Simko, J. P., . . . Tran, P. T. (2021). Validation of a 22-Gene Genomic Classifier in Patients with Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. JAMA Oncology, 7(4), 544-552.
Scopus73 WoS56 Europe PMC452021 Tewari, A. K., Gillessen, S., & Sweeney, C. J. (2021). Metastatic Prostate Cancer: In Search of More Granularity.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(26), JCO2100643.
Scopus5 WoS42021 Lage, D. E., Michaelson, M. D., Lee, R. J., Greer, J. A., Temel, J. S., & Sweeney, C. J. (2021). Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer. Prostate Cancer and Prostatic Diseases, 24(4), 1181-1188.
Scopus5 WoS4 Europe PMC32021 Rosenberg, J. E., Ballman, K. A., Halabi, S., Atherton, P. J., Mortazavi, A., Sweeney, C., . . . Morris, M. J. (2021). Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance).. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(22), 2486-2496.
Scopus26 WoS19 Europe PMC212021 Wang, V., Geybels, M., Jordahl, K. M., Gerke, T., Hamid, A., Penney, K., . . . Sweeney, C. J. (2021). A polymorphism in the promoter of the FRAS1 gene is associated with metastatic prostate cancer. The Prostate, 81(10), 683-693.
Scopus4 WoS4 Europe PMC42020 Gillessen, S., Attard, G., Beer, T. M., Beltran, H., Bjartell, A., Bossi, A., . . . Omlin, A. (2020). Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019[Formula presented]. European Urology, 77(4), 508-547.
Scopus288 Europe PMC1572020 Fankhauser, C. D., Sweeney, C. J., & Connors, J. M. (2020). Re: Rivaroxaban for Thromboprophylaxis in High-risk Ambulatory Patients with Cancer.. European urology, 77(3), 388-390.
Scopus3 WoS32020 Allott, E. H., Ebot, E. M., Stopsack, K. H., Gonzalez-Feliciano, A. G., Markt, S. C., Wilson, K. M., . . . Mucci, L. A. (2020). Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 26(5), 1086-1093.
Scopus33 WoS27 Europe PMC272020 Bernard, B., Burnett, C., Sweeney, C. J., Rider, J. R., & Sridhar, S. S. (2020). Impact of age at diagnosis of de novo metastatic prostate cancer on survival. Cancer, 126(5), 986-993.
Scopus33 WoS25 Europe PMC222020 Hearn, J. W. D., Sweeney, C. J., Almassi, N., Reichard, C. A., Reddy, C. A., Li, H., . . . Sharifi, N. (2020). HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer. JAMA Oncology, 6(4), 8 pages.
Scopus45 WoS37 Europe PMC312020 Kurzrock, R., Bowles, D. W., Kang, H., Meric-Bernstam, F., Hainsworth, J., Spigel, D. R., . . . Swanton, C. (2020). Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. Annals of Oncology, 31(3), 412-421.
Scopus81 WoS62 Europe PMC392020 Xie, W., Regan, M. M., Buyse, M., Halabi, S., Kantoff, P. W., Sartor, O., . . . Sweeney, C. J. (2020). Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 38(26), 3032-3041.
Scopus33 WoS28 Europe PMC182020 Font-Tello, A., Kesten, N., Xie, Y., Taing, L., Varešlija, D., Young, L. S., . . . Long, H. W. (2020). FiTAc-seq: fixed-tissue ChIP-seq for H3K27ac profiling and super-enhancer analysis of FFPE tissues. Nature Protocols, 15(8), 2503-2518.
Scopus16 Europe PMC152020 Kucharczyk, M. J., So, J., Gravis, G., Sweeney, C., Saad, F., & Niazi, T. (2020). A combined biological and clinical rationale for evaluating metastasis directed therapy in the management of oligometastatic prostate cancer. Radiotherapy and Oncology, 152, 80-88.
Scopus8 WoS8 Europe PMC42020 Tripathi, A., Supko, J. G., Gray, K. P., Melnick, Z., Regan, M. M., Taplin, M. -E., . . . Harshman, L. C. (2020). Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-Resistant Prostate Cancer: A Phase 1 Study of Concurrent Enzalutamide and Crizotinib.. Clin Cancer Res, 26(23), 6122-6131.
Scopus9 WoS7 Europe PMC52020 Vicier, C., Ravi, P., Kwak, L., Werner, L., Huang, Y., Evan, C., . . . Sweeney, C. J. (2020). Association between CD8 and PD-L1 expression and outcomes after radical prostatectomy for localized prostate cancer. Prostate, 81(1), 50-57.
Scopus20 WoS18 Europe PMC152020 Schmid, S., Omlin, A., Higano, C., Sweeney, C., Martinez Chanza, N., Mehra, N., . . . Gillessen, S. (2020). Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. JAMA network open, 3(10), 15 pages.
Scopus65 WoS39 Europe PMC432020 Bryce, A. H., Chen, Y. H., Liu, G., Carducci, M. A., Jarrard, D. M., Garcia, J. A., . . . Sweeney, C. J. (2020). Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial. European urology oncology, 3(6), 717-724.
Scopus13 WoS8 Europe PMC32020 Sundahl, N., Gillessen, S., Sweeney, C., & Ost, P. (2020). When What You See Is Not Always What You Get: Raising the Bar of Evidence for New Diagnostic Imaging Modalities. European Urology, 79(5), 565-567.
Scopus23 WoS19 Europe PMC112020 Chiorean, E. G., Perkins, S. M., Strother, R. M., Younger, A., Funke, J. M., Shahda, S. G., . . . Matei, D. E. (2020). Phase I, pharmacogenomic, drug-interaction study of sorafenib and bevacizumab in combination with paclitaxel in patients with advanced refractory solid tumors.. Molecular cancer therapeutics, 19(10), 2155-2162.
Scopus4 WoS4 Europe PMC22020 Harshman, L. C., Wang, V. X., Hamid, A. A., Santone, G., Drake, C. G., Carducci, M. A., . . . Sweeney, C. J. (2020). Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805). Prostate, 80(16), 1381-1449.
Scopus11 WoS9 Europe PMC82020 Fankhauser, C., Wettstein, M., Pedregal, M., Clarke, N., & Sweeney, C. (2020). A Call for Standardized Reporting of Adverse Events. European Urology, 78(3), 481-482.
Scopus2 Europe PMC22019 Xie, W., Halabi, S., Tierney, J. F., Sydes, M. R., Collette, L., Dignam, J. J., . . . Regan, M. M. (2019). A systematic review and recommendation for reporting of surrogate endpoint evaluation using meta-analyses. JNCI Cancer Spectrum, 3(1), 11 pages.
Scopus562019 Gillessen, S., Omlin, A., Attard, G., de Bono, J., Efstathiou, E., Fizazi, K., . . . Tombal, B. (2019). Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Annals of oncology : official journal of the European Society for Medical Oncology, 30(12), e3.
Scopus12 Europe PMC102019 Davis, I., Stockler, M., & Sweeney, C. (2019). Enzalutamide in Metastatic Prostate Cancer. Reply. The New England journal of medicine, 381(15), 1494-1495.
Scopus3 WoS32019 VanderWeele, D., Antonarakis, E., Carducci, M., Dreicer, R., Fizazi, K., Gillessen, S., . . . Hussain, M. (2019). Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 37(32), 2961-2967.
Scopus10 WoS11 Europe PMC72019 Sweeney, C. J., & Beltran, H. (2019). The Balancing Act: Assessing Treatment Burden Versus Treatment Benefit with Evolving Metastatic Hormone-sensitive Prostate Cancer Data.. European urology, 76(6), 729-731.
2019 Sweeney, C., De Abreu Lourenco, R., Hamid, A., & Buyse, M. (2019). What does metastasis-free survival actually mean?. Journal of Clinical Oncology, 37(19), 1679-1680.
Scopus1 Europe PMC12019 Hamid, A. A., Gray, K. P., Huang, Y., Bowden, M., Pomerantz, M., Loda, M., & Sweeney, C. J. (2019). Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy.. European urology oncology, 2(5), 475-482.
Scopus17 WoS19 Europe PMC142019 McKay, R., Mills, H., Werner, L., Choudhury, A., Choueiri, T., Jacobus, S., . . . Taplin, M. E. (2019). Evaluating a video-based, personalized webpage in genitourinary oncology clinical trials: A phase 2 randomized trial. Journal of Medical Internet Research, 21(5), 17 pages.
Scopus3 WoS3 Europe PMC22019 Francini, E., Gray, K. P., Shaw, G. K., Evan, C. P., Hamid, A. A., Perry, C. E., . . . Sweeney, C. J. (2019). Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry. Prostate Cancer and Prostatic Diseases, 22(3), 420-427.
Scopus49 WoS41 Europe PMC292019 Morel, K. L., Ormsby, R. J., Klebe, S., Sweeney, C. J., & Sykes, P. J. (2019). DMAPT is an Effective Radioprotector from Long-Term Radiation-Induced Damage to Normal Mouse Tissues In Vivo. Radiation research, 192(2), 231-239.
Scopus5 WoS5 Europe PMC22019 Morris, M. J., Loriot, Y., Sweeney, C. J., Fizazi, K., Ryan, C. J., Shevrin, D. H., . . . Higano, C. S. (2019). Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. European Journal of Cancer, 114, 107-116.
Scopus35 WoS30 Europe PMC172019 Stoneham, S., Murray, M., Thomas, B., Williamson, M., Sweeney, C., & Frazier, L. (2019). AYA testis cancer: The unmet challenge. Pediatric Blood and Cancer, 66(8), 8 pages.
Scopus4 WoS3 Europe PMC22019 Salgado, R., Solit, D. B., Rimm, D. L., Bogaerts, J., Canetta, R., Lively, T., . . . Golfinopoulos, V. (2019). Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. European Journal of Cancer, 114, 128-136.
Scopus7 WoS6 Europe PMC42019 McGregor, B. A., Miller, R. E., O'Donnell, E., Albiges, L. K., Sweeney, C. J., & Markt, S. C. (2019). Body Mass Index and Outcomes in Germ-Cell Tumors. Clinical Genitourinary Cancer, 17(4), 283-290.
Scopus2 WoS1 Europe PMC22019 Davis, I. D., Martin, A. J., Stockler, M. R., Begbie, S., Chi, K. N., Chowdhury, S., . . . Sweeney, C. J. (2019). Enzalutamide with standard first-line therapy in metastatic prostate cancer. New England Journal of Medicine, 381(2), 121-131.
Scopus917 WoS766 Europe PMC4832019 Santos, J. M. O., Moreira-Pais, A., Neto, T., Peixoto da Silva, S., Oliveira, P. A., Ferreira, R., . . . Gil da Costa, R. M. (2019). Dimethylaminoparthenolide reduces the incidence of dysplasia and ameliorates a wasting syndrome in HPV16-transgenic mice. Drug Development Research, 80(6), 7 pages.
Scopus13 WoS10 Europe PMC72019 Logothetis, C. J., Saad, F., Sweeney, C., Taplin, M. E., & Fizazi, K. (2019). Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer. European Urology, 75(1), 44-60.
Scopus47 WoS43 Europe PMC212019 Hamid, A. A., Markt, S. C., Vicier, C., McDermott, K., Richardson, P., Ho, V. T., & Sweeney, C. J. (2019). Autologous Stem-Cell Transplantation Outcomes for Relapsed Metastatic Germ-Cell Tumors in the Modern Era. Clinical Genitourinary Cancer, 17(1), 58-64.e1.
Scopus8 WoS7 Europe PMC42019 Vicier, C., Werner, L., Chipman, J., Harshman, L. C., Patil, D. H., Fichorova, R. N., . . . Sweeney, C. J. (2019). Elevated Serum Cytokines and Trichomonas vaginalis Serology at Diagnosis Are Not Associated With Higher Gleason Grade or Lethal Prostate Cancer. Clinical Genitourinary Cancer, 17(1), 32-37.
Scopus4 WoS5 Europe PMC32019 Gerke, T., Beltran, H., Wang, X., Lee, G. S. M., Sboner, A., Karnes, R. J., . . . Sweeney, C. J. (2019). Low tristetraprolin expression is associated with lethal prostate cancer. Cancer Epidemiology Biomarkers and Prevention, 28(3), 584-590.
Scopus7 WoS5 Europe PMC32019 McKay, R. R., Werner, L., Jacobus, S. J., Jones, A., Mostaghel, E. A., Marck, B. T., . . . Taplin, M. E. (2019). A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer. Cancer, 125(4), 524-532.
Scopus8 WoS7 Europe PMC52019 Withington, J., Cole, A. P., Meyer, C. P., Seisen, T., Schmid, M., Lipsitz, S. R., . . . Trinh, Q. D. (2019). Comparison of testis cancer-specific survival: an analysis of national cancer registry data from the USA, UK and Germany. BJU International, 123(3), 385-387.
Scopus5 WoS4 Europe PMC32019 Hamid, A. A., Gray, K. P., Shaw, G., MacConaill, L. E., Evan, C., Bernard, B., . . . Sweeney, C. J. (2019). Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer. European Urology, 76(1), 89-97.
Scopus147 WoS126 Europe PMC1042019 Vapiwala, N., Hofman, M., Murphy, D., Williams, S., & Sweeney, C. (2019). Strategies for evaluation of novel imaging in prostate cancer: Putting the horse back before the cart. Journal of Clinical Oncology, 37(10), 765-769.
Scopus28 WoS28 Europe PMC102019 Burdett, S., Boevé, L. M., Ingleby, F. C., Fisher, D. J., Rydzewska, L. H., Vale, C. L., . . . Tierney, J. F. (2019). Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis. European Urology, 76(1), 115-124.
Scopus174 WoS147 Europe PMC842019 Meric-Bernstam, F., Hurwitz, H., Raghav, K. P. S., McWilliams, R. R., Fakih, M., VanderWalde, A., . . . Hainsworth, J. (2019). Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. The Lancet Oncology, 20(4), 518-530.
Scopus351 WoS276 Europe PMC1952019 Sweeney, C. (2019). Time for an Integrated Global Strategy to Decrease Deaths from Prostate Cancer. European Urology Focus, 5(2), 111-113.
Scopus3 WoS3 Europe PMC32019 Aldubayan, S. H., Pyle, L. C., Gamulin, M., Kulis, T., Moore, N. D., Taylor-Weiner, A., . . . Lessel, D. (2019). Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) with Susceptibility to Testicular Germ Cell Tumors. JAMA Oncology, 5(4), 514-522.
Scopus40 WoS33 Europe PMC242019 Mateo, J., Fizazi, K., Gillessen, S., Heidenreich, A., Perez-Lopez, R., Oyen, W. J. G., . . . de Bono, J. S. (2019). Managing Nonmetastatic Castration-resistant Prostate Cancer. European Urology, 75(2), 285-293.
Scopus114 WoS104 Europe PMC532018 Hainsworth, J. D., Meric-Bernstam, F., Swanton, C., Hurwitz, H., Spigel, D. R., Sweeney, C., . . . Kurzrock, R. (2018). Reply to J.J. Tao et al. Journal of Clinical Oncology, 36(23), 2451.
Scopus2 Europe PMC12018 Morel, K. L., Ormsby, R. J., Solly, E. L., Tran, L. N. K., Sweeney, C. J., Klebe, S., . . . Sykes, P. J. (2018). Chronic low dose ethanol induces an aggressive metastatic phenotype in TRAMP mice, which is counteracted by parthenolide. Clinical and Experimental Metastasis, 35(7), 649-661.
Scopus7 WoS6 Europe PMC42018 Sweeney, C. J. (2018). Having Found Meaningful Intermediate Prostate Cancer Clinical Endpoints Associated with Overall Survival, What Next?. European Urology, 74(4), 420-421.
2018 Francini, E., Gray, K. P., Xie, W., Shaw, G. K., Valença, L., Bernard, B., . . . Sweeney, C. J. (2018). Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate, 78(12), 889-895.
Scopus99 WoS89 Europe PMC372018 Komura, K., Yoshikawa, Y., Shimamura, T., Chakraborty, G., Gerke, T. A., Hinohara, K., . . . Kantoff, P. W. (2018). ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D. Journal of Clinical Investigation, 128(7), 2979-2995.
Scopus49 WoS43 Europe PMC352018 Choudhury, A. D., Gray, K. P., Supko, J. G., Harshman, L. C., Taplin, M. E., Pace, A. F., . . . Sweeney, C. (2018). A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate, 78(14), 1053-1062.
Scopus6 WoS6 Europe PMC32018 Sartor, O., Vogelzang, N., Sweeney, C., Fernandez, D., Almeida, F., Iagaru, A., . . . Morris, M. (2018). Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program. Oncologist, 23(2), 193-202.
Scopus59 WoS51 Europe PMC242018 Vale, C., Fisher, D., White, I., Carpenter, J., Burdett, S., Clarke, N., . . . Tierney, J. (2018). What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis. Annals of Oncology, 29(5), 1249-1257.
Scopus59 WoS48 Europe PMC302018 Komura, K., Sweeney, C., Inamoto, T., Ibuki, N., Azuma, H., & Kantoff, P. (2018). Current treatment strategies for advanced prostate cancer. International Journal of Urology, 25(3), 220-231.
Scopus166 WoS154 Europe PMC992018 Harshman, L., Chen, Y., Liu, G., Carducci, M., Jarrard, D., Dreicer, R., . . . Sweeney, C. (2018). Seven-month prostate-specific antigen is prognostic in metastatic hormone-sensitive prostate cancer treated with androgen deprivation with or without docetaxel. Journal of Clinical Oncology, 36(4), 376-382.
Scopus70 WoS60 Europe PMC382018 McNamara, M., Sweeney, C., Antonarakis, E. S., & Armstrong, A. J. (2018). The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation. Prostate Cancer and Prostatic Diseases, 21(3), 306-318.
Scopus27 WoS24 Europe PMC112018 Harshman, L., Xie, W., Moreira, R., Bossé, D., Ruiz Ares, G., Sweeney, C., & Choueiri, T. (2018). Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis. Cancer, 124(5), 925-933.
Scopus33 WoS30 Europe PMC202018 Francini, E., Yip, S., Ahmed, S., Li, H., Ardolino, L., Evan, C. P., . . . Sweeney, C. J. (2018). Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer. Clinical Genitourinary Cancer, 16(2), 130-134.
Scopus17 WoS15 Europe PMC82018 Hainsworth, J. D., Meric-Bernstam, F., Swanton, C., Hurwitz, H., Spigel, D. R., Sweeney, C., . . . Kurzrock, R. (2018). Targeted therapy for advanced solid tumors on the basis of molecular profiles: Results from mypathway, an open-label, phase IIA multiple basket study. Journal of Clinical Oncology, 36(6), 536-542.
Scopus338 WoS288 Europe PMC2282018 Kyriakopoulos, C. E., Chen, Y. H., Carducci, M. A., Liu, G., Jarrard, D. F., Hahn, N. M., . . . Sweeney, C. J. (2018). Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 chaarted trial. Journal of Clinical Oncology, 36(11), 1080-1087.
Scopus680 WoS570 Europe PMC3412018 Xie, W., Regan, M., & Sweeney, C. (2018). Reply to Y. Zhu et al. Journal of Clinical Oncology, 36(5), 515-516.
Europe PMC72018 Gravis, G., Boher, J. M., Chen, Y. H., Liu, G., Fizazi, K., Carducci, M. A., . . . Sweeney, C. (2018). Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. European Urology, 73(6), 847-855.
Scopus161 WoS148 Europe PMC662018 Morgans, A. K., Chen, Y. H., Sweeney, C. J., Jarrard, D. F., Plimack, E. R., Gartrell, B. A., . . . Patrick-Miller, L. J. (2018). Quality of life during treatment with chemohormonal therapy: Analysis of E3805 chemohormonal androgen ablation randomized trial in prostate cancer. Journal of Clinical Oncology, 36(11), 1088-1095.
Scopus65 WoS62 Europe PMC362018 Deraska, P. V., O Leary, C., Reavis, H. D., Labe, S., Dinh, T. K., Lazaro, J. B., . . . Kozono, D. (2018). NF-κB inhibition by dimethylaminoparthenolide radiosensitizes non-small-cell lung carcinoma by blocking DNA double-strand break repair. Cell Death Discovery, 4(1), 12 pages.
Scopus17 WoS14 Europe PMC132018 Dinh, K. T., Aizer, A. A., Muralidhar, V., Mahal, B. A., Chen, Y. W., Beard, C. J., . . . Nguyen, P. L. (2018). Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce. American Journal of Medicine, 131(5), 517-523.
Scopus11 WoS9 Europe PMC62018 Gillessen, S., Attard, G., Beer, T., Beltran, H., Bossi, A., Bristow, R., . . . Omlin, A. (2018). Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 [Figure presented]. European Urology, 73(2), 178-211.
Scopus386 WoS356 Europe PMC1982018 Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M., . . . Ryan, S. (2018). Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. The Lancet, 391(10125), 1023-1075.
Scopus3057 Europe PMC18882018 Wong, S., North, S., Sweeney, C., Stockler, M., & Sridhar, S. (2018). Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies. Clinical Genitourinary Cancer, 16(1), 233-242.
Scopus5 WoS5 Europe PMC42018 O'Donnell, E., Markt, S., Miller, R., Bernard, B., Albiges, L., Beard, C., & Sweeney, C. (2018). Smoking and Disease Outcomes in Patients With Malignant Germ Cell Tumors. Clinical Genitourinary Cancer, 16(1), 78-84.
Scopus5 Europe PMC42017 Qu, F., Xie, W., Nakabayashi, M., Zhang, H., Jeong, S., Wang, X., . . . Kantoff, P. (2017). Association of AR-V7 and prostate-specific antigen RNA levels in blood with efficacy of abiraterone acetate and enzalutamide treatment in men with prostate cancer. Clinical Cancer Research, 23(3), 726-734.
Scopus84 WoS81 Europe PMC632017 Miller, R., Markt, S., O'Donnell, E., Bernard, B., Albiges, L., Beard, C., & Sweeney, C. (2017). Age ≥40 Years Is Associated with Adverse Outcome in Metastatic Germ Cell Cancer Despite Appropriate Intended Chemotherapy. European Urology Focus, 3(6), 621-628.
Scopus11 WoS9 Europe PMC72017 Guinney, J., Wang, T., Laajala, T. D., Winner, K. K., Bare, J. C., Neto, E. C., . . . Costello, J. C. (2017). Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. The Lancet Oncology, 18(1), 132-142.
Scopus105 WoS93 Europe PMC832017 Matz, M., Coleman, M., Carreira, H., Salmerón, D., Chirlaque, M., Allemani, C., . . . Stuart-Panko, H. (2017). Erratum to “Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2)” [Gynecol. Oncol. 144 (2017) 396–404](S009082581631575X)(10.1016/j.ygyno.2016.11.019). Gynecologic Oncology, 147(3), 725.
Scopus2 Europe PMC12017 Matz, M., Coleman, M., Sant, M., Chirlaque, M., Visser, O., Gore, M., . . . Robb, K. (2017). Erratum to “The histology of ovarian cancer: Worldwide distribution and implications for international survival comparisons (CONCORD-2)” [Gynecol. Oncol. 144 (2017) 405–413](S0090825816314974)(10.1016/j.ygyno.2016.10.019). Gynecologic Oncology, 147(3), 726.
Scopus22017 Bonaventure, A., Harewood, R., Stiller, C. A., Gatta, G., Clavel, J., Stefan, D. C., . . . Ruta, M. (2017). Worldwide comparison of survival from childhood leukaemia for 1995–2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries. The Lancet Haematology, 4(5), e202-e217.
Scopus144 Europe PMC742017 Matz, M., Coleman, M. P., Sant, M., Chirlaque, M. D., Visser, O., Gore, M., . . . Robb, K. I. (2017). The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2). Gynecologic Oncology, 144(2), 405-413.
Scopus96 Europe PMC572017 Matz, M., Coleman, M. P., Carreira, H., Salmerón, D., Chirlaque, M. D., Allemani, C., . . . Stuart-Panko, H. (2017). Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2). Gynecologic Oncology, 144(2), 396-404.
Scopus92 Europe PMC562017 Harshman, L. C., Werner, L., Tripathi, A., Wang, X., Maughan, B. L., Antonarakis, E. S., . . . Kantoff, P. W. (2017). The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer. Prostate, 77(13), 1303-1311.
Scopus17 WoS14 Europe PMC152017 Rydzewska, L. H. M., Burdett, S., Vale, C. L., Clarke, N. W., Fizazi, K., Kheoh, T., . . . Tierney, J. F. (2017). Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. European Journal of Cancer, 84, 88-101.
Scopus123 WoS106 Europe PMC602017 Hamid, A., & Sweeney, C. (2017). Prostate cancer: A new standard-of-care for advanced-stage disease. Nature Reviews Clinical Oncology, 14(10), 592-593.
Scopus4 WoS4 Europe PMC12017 Xie, W., Regan, M. M., Buyse, M., Halabi, S., Kantoff, P. W., Sartor, O., . . . Zapatero, A. (2017). Metastasis-free survival is a strong Surrogate of overall survival in localized prostate cancer. Journal of Clinical Oncology, 35(27), 3097-3104.
Scopus319 WoS288 Europe PMC1612017 Pezaro, C. J., Omlin, A., Mastris, K., Attard, G., Beer, T. M., Chi, K. N., . . . Gillessen, S. (2017). Precision, complexity and stigma in advanced prostate cancer terminology: It is time to move away from 'castration-resistant' prostate cancer. Annals of Oncology, 28(8), 1692-1694.
Scopus4 WoS4 Europe PMC22017 Dorff, T. B., & Sweeney, C. J. (2017). Chemotherapy for oligometastatic prostate cancer. Current Opinion in Urology, 27(6), 553-558.
Scopus5 WoS4 Europe PMC42017 Labbé, D. P., Sweeney, C. J., Brown, M., Galbo, P., Rosario, S., Wadosky, K. M., . . . Ellis, L. (2017). TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup. Clinical Cancer Research, 23(22), 7072-7083.
Scopus75 WoS70 Europe PMC592017 Bernard, B., Muralidhar, V., Chen, Y. H., Sridhar, S. S., Mitchell, E. P., Pettaway, C. A., . . . Sweeney, C. J. (2017). Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer. Cancer, 123(9), 1536-1544.
Scopus57 WoS52 Europe PMC292017 Clement, J. M., & Sweeney, C. J. (2017). Evolving treatment of oligometastatic hormone-sensitive prostate cancer. Journal of Oncology Practice, 13(1), 9-18.
Scopus15 WoS14 Europe PMC132017 Perez-Gracia, J. L., Sanmamed, M. F., Bosch, A., Patiño-Garcia, A., Schalper, K. A., Segura, V., . . . Melero, I. (2017). Strategies to design clinical studies to identify predictive biomarkers in cancer research. Cancer Treatment Reviews, 53, 79-97.
Scopus75 WoS66 Europe PMC382017 Murphy, D. G., Sweeney, C. J., & Tombal, B. (2017). “Gotta Catch ‘em All”, or Do We? Pokemet Approach to Metastatic Prostate Cancer. European Urology, 72(1), 1-3.
Scopus54 WoS53 Europe PMC312017 Morel, K. L., Ormsby, R. J., Bezak, E., Sweeney, C. J., & Sykes, P. J. (2017). Parthenolide Selectively Sensitizes Prostate Tumor Tissue to Radiotherapy while Protecting Healthy Tissues in Vivo. Radiation Research, 187(5), 501-512.
Scopus29 WoS27 Europe PMC162017 Mahal, B. A., Chen, Y. W., Muralidhar, V., Mahal, A. R., Choueiri, T. K., Hoffman, K. E., . . . Nguyen, P. L. (2017). Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. Annals of oncology : official journal of the European Society for Medical Oncology, 28(5), 1098-1104.
Scopus37 WoS38 Europe PMC232017 Muralidhar, V., Mahal, B., Rose, B., Chen, Y., Nezolosky, M., Efstathiou, J., . . . Nguyen, P. (2017). Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. Clinical Genitourinary Cancer, 15(5), 563-569.e3.
Scopus7 WoS6 Europe PMC32017 Seyednasrollah, F., Koestler, D. C., Wang, T., Piccolo, S. R., Vega, R., Greiner, R., . . . Lin, H. (2017). A DREAM challenge to build prediction models for short-term discontinuation of docetaxel in metastatic castration- resistant prostate cancer. JCO Clinical Cancer Informatics, 2017(1), 1-15.
Scopus14 WoS11 Europe PMC72016 Briganti, A., De Santis, M., Giannarini, G., & Sweeney, C. J. (2016). Delivering Optimal Care for Metastatic Prostate Cancer: A Strengthening Alliance Between Urologists and Medical Oncologists. European Urology Focus, 2(5), 463-464.
Scopus1 WoS12016 Lorente, D., Fizazi, K., Sweeney, C., & de Bono, J. S. (2016). Optimal Treatment Sequence for Metastatic Castration-resistant Prostate Cancer. European Urology Focus, 2(5), 488-498.
Scopus38 WoS36 Europe PMC182016 Sweeney, C., Chen, Y. H., Liu, G., Carducci, M., Jarrard, D., Eisenberger, M., . . . Dipaola, R. (2016). Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHAARTED trial. Annals of Oncology, 27, vi244.
Scopus422016 Taylor-Weiner, A., Zack, T., O'Donnell, E., Guerriero, J. L., Bernard, B., Reddy, A., . . . Van Allen, E. M. (2016). Genomic evolution and chemoresistance in germ-cell tumours. Nature, 540(7631), 114-118.
Scopus124 WoS112 Europe PMC902016 Mahal, B. A., Chen, Y. W., Muralidhar, V., Mahal, A. R., Choueiri, T. K., Hoffman, K. E., . . . Nguyen, P. L. (2016). National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers?. Cancer, 122(21), 3371-3377.
Scopus22 WoS23 Europe PMC122016 Sadow, C. A., Maurer, A. N., Prevedello, L. M., Sweeney, C. J., & Silverman, S. G. (2016). CT restaging of testicular germ cell tumors: the incidence of isolated pelvic metastases. European Journal of Radiology, 85(8), 1439-1444.
Scopus3 WoS3 Europe PMC12016 Chen, Y. W., Muralidhar, V., Mahal, B. A., Nezolosky, M. D., Beard, C. J., Choueiri, T. K., . . . Nguyen, P. L. (2016). Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. Brachytherapy, 15(6), 695-700.
Scopus14 WoS13 Europe PMC72016 Markt, S. C., Lago-Hernandez, C. A., Miller, R. E., Mahal, B. A., Bernard, B., Albiges, L., . . . Sweeney, C. J. (2016). Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors. Cancer, 122(20), 3127-3135.
Scopus50 WoS50 Europe PMC302016 Bernard, B., Gershman, B., Karnes, R., Sweeney, C., & Vapiwala, N. (2016). Approach to oligometastatic prostate cancer. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting, 35, 119-129.
Scopus17 Europe PMC142016 Zheng, D., Gui, B., Gray, K. P., Tinay, I., Rafiei, S., Huang, Q., . . . Jia, L. (2016). Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer. Oncogene, 35(36), 4807-4815.
Scopus28 WoS25 Europe PMC162016 Dinh, K., Reznor, G., Muralidhar, V., Mahal, B., Nezolosky, M., Choueiri, T., . . . Nguyen, P. (2016). Association of androgen deprivation therapy with depression in localized prostate cancer. Journal of Clinical Oncology, 34(16), 1905-1912.
Scopus113 WoS102 Europe PMC732016 McKay, R. R., Zurita, A. J., Werner, L., Bruce, J. Y., Carducci, M. A., Stein, M. N., . . . Taplin, M. E. (2016). A randomized phase II trial of short-course androgen deprivation therapy with or without bevacizumab for patients with recurrent prostate cancer after definitive local therapy. Journal of Clinical Oncology, 34(16), 1913-1920.
Scopus33 WoS28 Europe PMC262016 Komura, K., Jeong, S. H., Hinohara, K., Qu, F., Wang, X., Hiraki, M., . . . Sweeney, C. J. (2016). Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression. Proceedings of the National Academy of Sciences of the United States of America, 113(22), 6259-6264.
Scopus113 WoS97 Europe PMC752016 Kryukov, G. V., Bielski, C. M., Samocha, K., Fromer, M., Seepo, S., Gentry, C., . . . Van Allen, E. M. (2016). Genetic Effect of Chemotherapy Exposure in Children of Testicular Cancer Survivors. Clinical Cancer Research, 22(9), 2183-2189.
Scopus14 WoS13 Europe PMC42016 McKay, R., De Velasco, G., Werner, L., Bellmunt, J., Harshman, L., Sweeney, C., . . . Choueiri, T. (2016). A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies. Cancer, 122(15), 2389-2398.
Scopus17 WoS14 Europe PMC122016 Börnigen, D., Tyekucheva, S., Wang, X., Rider, J. R., Lee, G. S., Mucci, L. A., . . . Huttenhower, C. (2016). Computational reconstruction of NFκB pathway interaction mechanisms during prostate cancer. PLoS Computational Biology, 12(4), e1004820-1-e1004820-30.
Scopus21 WoS19 Europe PMC142016 Muralidhar, V., Catalano, P., Reznor, G., Mahal, B., Choueiri, T., Sweeney, C., . . . Nguyen, P. (2016). Variation in national use of long-term ADT by disease aggressiveness among men with unfavorable-risk prostate cancer. Journal of the National Comprehensive Cancer Network, 14(4), 421-428.
Scopus10 WoS9 Europe PMC32016 Ko, J. J., Bernard, B., Tran, B., Li, H., Asif, T., Stukalin, I., . . . Heng, D. Y. C. (2016). Conditional survival of patients with metastatic testicular germ cell tumors treated with first-line curative therapy. Journal of Clinical Oncology, 34(7), 714-720.
Scopus34 WoS31 Europe PMC172016 Cejas, P., Li, L., O'Neill, N. K., Duarte, M., Rao, P., Bowden, M., . . . Long, H. W. (2016). Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profiles. Nature Medicine, 22(6), 685-691.
Scopus54 WoS45 Europe PMC392016 Nezolosky, M., Dinh, K., Muralidhar, V., Mahal, B., Chen, Y., Beard, C., . . . Nguyen, P. (2016). Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012. Urologic Oncology: Seminars and Original Investigations, 34(2), 57.e15-57.e22.
Scopus17 WoS5 Europe PMC82016 Vale, C., Burdett, S., Rydzewska, L., Albiges, L., Clarke, N., Fisher, D., . . . Tierney, J. (2016). Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. The Lancet Oncology, 17(2), 243-256.
Scopus342 WoS294 Europe PMC1852016 Muralidhar, V., Regan, M. M., Werner, L., Nakabayashi, M., Evan, C. P., Bellmunt, J., . . . Nguyen, P. L. (2016). Duration of androgen deprivation therapy for high-risk prostate cancer: application of randomized trial data in a tertiary referral cancer center. Clinical Genitourinary Cancer, 14(4), e299-e305.
Scopus10 WoS8 Europe PMC42016 Garcia, J. A., & Sweeney, C. (2016). Chemohormonal Therapy in Hormone-Sensitive Prostate Cancer. The New England journal of medicine, 374(3), 287.
Scopus12016 Feldman, D., Lorch, A., Kramar, A., Albany, C., Einhorn, L., Giannatempo, P., . . . Powles, T. (2016). Brain metastases in patients with germ cell tumors: prognostic factors and treatment options - an analysis from the Global Germ Cell Cancer Group. Journal of Clinical Oncology, 34(4), 345-351.
Scopus62 WoS53 Europe PMC312016 Lu, D., Sinnott, J. A., Valdimarsdottir, U., Fang, F., Gerke, T., Tyekucheva, S., . . . Fall, K. (2016). Stress-Related signaling pathways in lethal and nonlethal prostate cancer. Clinical Cancer Research, 22(3), 765-772.
Scopus23 WoS16 Europe PMC172016 Rudman, S. M., Gray, K. P., Batista, J. L., Pitt, M. J., Giovannucci, E. L., Harper, P. G., . . . Sweeney, C. J. (2016). Risk of prostate cancer-specific death in men with baseline metabolic aberrations treated with androgen deprivation therapy for biochemical recurrence. BJU International, 118(6), 919-926.
Scopus9 WoS7 Europe PMC42016 Dinh, K. T., Muralidhar, V., Mahal, B. A., Chen, Y. W., Nezolosky, M. D., Beard, C. J., . . . Nguyen, P. L. (2016). Occult High-risk Disease in Clinically Low-risk Prostate Cancer with ≥50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk?. Urology, 87, 125-132.
Scopus17 WoS16 Europe PMC112016 Sridhar, S. S., & Sweeney, C. J. (2016). It Is Time to Harmonize the Design and Conduct of Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer. European Urology, Online(2), 1-2.
Scopus3 WoS32016 Harshman, L. C., Wang, X., Nakabayashi, M., Xie, W., Valenca, L., Werner, L., . . . Kantoff, P. W. (2016). Re: Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients with Hormone-Sensitive Prostate Cancer Editorial Comment. JOURNAL OF UROLOGY, 195(6), 1780-1781.
WoS12016 Francini, E., & Sweeney, C. J. (2016). Docetaxel Activity in the Era of Life-prolonging Hormonal Therapies for Metastatic Castration-resistant Prostate Cancer. European Urology, 70(3), 410-412.
Scopus28 WoS27 Europe PMC162016 Miller, R. E., & Sweeney, C. J. (2016). Chemotherapy for metastatic castrate-sensitive prostate cancer. Prostate Cancer and Prostatic Diseases, 19(2), 139-144.
Scopus11 WoS9 Europe PMC72016 Mahal, B., Muralidhar, V., Chen, Y., Choueiri, T., Hoffman, K., Hu, J., . . . Nguyen, P. (2016). Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9?. BJU International, 118(1), 95-101.
Scopus45 WoS36 Europe PMC222016 Muralidhar, V., Mahal, B., Nezolosky, M., Beard, C., Feng, F., Martin, N., . . . Nguyen, P. (2016). Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancer. BJU International, 118(2), 279-285.
Scopus11 WoS9 Europe PMC72016 Giannatempo, P., Pond, G. R., Sonpavde, G., Albany, C., Loriot, Y., Sweeney, C. J., . . . Cary, C. (2016). Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration. Journal of Urology, 196(1), 95-100.
Scopus58 Europe PMC342016 Dinh, K. T., Mahal, B. A., Ziehr, D. R., Muralidhar, V., Chen, Y. W., Viswanathan, V. B., . . . Nguyen, P. L. (2016). Risk of prostate cancer mortality in men with a history of prior cancer. BJU International, 117(6), E20-E28.
Scopus20 WoS19 Europe PMC142015 Hsieh, C., Botta, G., Gao, S., Li, T., Van Allen, E., Treacy, D., . . . Kantoff, P. (2015). PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy. Cancer Research, 75(10), 1944-1948.
Scopus41 WoS39 Europe PMC352015 Pal, S., Azad, A., Bhatia, S., Drabkin, H., Costello, B., Sarantopoulos, J., . . . Hutson, T. (2015). A phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma. Clinical Cancer Research, 21(15), 3420-3427.
Scopus30 WoS25 Europe PMC102015 Chiorean, E. G., Hurwitz, H. I., Cohen, R. B., Schwartz, J. D., Dalal, R. P., Fox, F. E., . . . Sweeney, C. J. (2015). Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors. Annals of Oncology, 26(6), 1230-1237.
Scopus63 WoS58 Europe PMC482015 Valenca, L. B., Sweeney, C. J., & Pomerantz, M. M. (2015). Sequencing current therapies in the treatment of metastatic prostate cancer. Cancer Treatment Reviews, 41(4), 332-340.
Scopus39 WoS34 Europe PMC202015 Bernard, B., & Sweeney, C. J. (2015). Management of Metastatic Hormone-Sensitive Prostate Cancer. Current Urology Reports, 16(3), 8 pages.
Scopus11 WoS11 Europe PMC82015 Mahal, B., Cooperberg, M., Aizer, A., Ziehr, D., Hyatt, A., Choueiri, T., . . . Nguyen, P. (2015). Who bears the greatest burden of aggressive treatment of indolent prostate cancer?. American Journal of Medicine, 128(6), 609-616.
Scopus15 WoS13 Europe PMC92015 Zukotynski, K., Kim, C., Gerbaudo, V., Hainer, J., Taplin, M. -E., Kantoff, P., . . . Sweeney, C. (2015). ¹⁸F-FDG-PET/CT and ¹⁸F-NaF-PET/CT in men with castrate-resistant prostate cancer. American Journal of Nuclear Medicine and Molecular Imaging, 5(1), 72-82.
Europe PMC112015 Nakshatri, H., Appaiah, H. N., Anjanappa, M., Gilley, D., Tanaka, H., Badve, S., . . . Bhat-Nakshatri, P. (2015). Nf-kB-dependent and -independent epigenetic modulation using the novel anti-cancer agent DMAPT. Cell Death and Disease, 6(1), 11 pages.
Scopus45 WoS41 Europe PMC312015 Wood, M., Tirumani, S., Sweeney, C., Ramaiya, N., & Howard, S. (2015). Approach to risk stratification in testicular germ cell tumors: a primer for radiologists. Abdominal Imaging, 40(6), 1871-1886.
Scopus3 WoS2 Europe PMC22015 Ziehr, D., Mahal, B., Aizer, A., Hyatt, A., Beard, C., D'Amico, A., . . . Nguyen, P. (2015). Income inequality and treatment of African American men with high-risk prostate cancer. Urologic oncology, 33(1), 18.e7-18.e13.
Scopus51 WoS46 Europe PMC352015 Ziehr, D., Chen, M., Zhang, D., Braccioforte, M., Moran, B., Mahal, B., . . . Nguyen, P. (2015). Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. BJU International, 116(3), 358-365.
Scopus64 WoS52 Europe PMC352015 Börnigen, D., Moon, Y., Rahnavard, G., Waldron, L., McIver, L., Shafquat, A., . . . Huttenhower, C. (2015). A reproducible approach to high-throughput biological data acquisition and integration. PeerJ, 3(3), e791-1-e791-35.
Scopus10 WoS8 Europe PMC92015 Sweeney, C. J. (2015). Insights into E3805: The CHAARTED trial. Future Oncology, 11(6), 897-899.
Scopus9 WoS9 Europe PMC62015 Muralidhar, V., Dinh, K., Mahal, B., Ziehr, D., Chen, Y., Viswanathan, V., . . . Nguyen, P. (2015). Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: implications for managing patients upstaged on prostate magnetic resonance imaging. Urologic Oncology, 33(7), 300.e19-300.e25.
Scopus12 Europe PMC62015 Lago-Hernandez, C., Feldman, H., O'Donnell, E., Mahal, B., Perez, V., Howard, S., . . . Sweeney, C. (2015). A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion. Annals of Oncology, 26(7), 1396-1401.
Scopus31 WoS28 Europe PMC212015 Basch, E., Autio, K., Smith, M., Bennett, A., Weitzman, A., Scheffold, C., . . . Scher, H. (2015). Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: Results from a phase 2 nonrandomized expansion cohort. European Urology, 67(2), 310-318.
Scopus35 WoS30 Europe PMC242015 Graff, R., Pettersson, A., Lis, R., Dupre, N., Jordahl, K., Nuttall, E., . . . Mucci, L. (2015). The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer. Prostate, 75(9), 897-906.
Scopus25 WoS22 Europe PMC232015 McCall, K. C., Cheng, S. C., Huang, Y., Kohf, N. E., Tupper, T., Van den Abbeele, A. D., . . . Sweeney, C. J. (2015). [¹⁸F]-fluorodeoxyglucose positron emission tomography computed tomography of LAPC4-CR castration-resistant prostate cancer xenograft mod in soft tissue compartments. Translational Oncology, 8(3), 147-153.
Scopus5 WoS3 Europe PMC22015 Gillessen, S., Omlin, A., Attard, G., de Bono, J. S., Efstathiou, E., Fizazi, K., . . . Tombal, B. (2015). Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Annals of Oncology, 26(8), 1589-1604.
Scopus264 WoS221 Europe PMC1522015 Muralidhar, V., Ziehr, D., Mahal, B., Chen, Y., Nezolosky, M., Viswanathan, V., . . . Nguyen, P. (2015). Association between older age and increasing gleason score. Clinical Genitourinary Cancer, 13(6), 525-530e3.
Scopus24 WoS19 Europe PMC102015 Olson, T. A., Murray, M. J., Rodriguez-Galindo, C., Nicholson, J. C., Billmire, D. F., Krailo, M. D., . . . Frazier, A. L. (2015). Pediatric and adolescent extracranial germ cell tumors: The road to collaboration. Journal of Clinical Oncology, 33(27), 3018-3028.
Scopus64 WoS47 Europe PMC332015 Wang, X., Huang, Y., Christie, A., Bowden, M., Lee, G., Kantoff, P., & Sweeney, C. (2015). Cabozantinib inhibits abiraterone's upregulation of IGFIR phosphorylation and enhances its anti-prostate cancer activity. Clinical Cancer Research, 21(24), 5578-5587.
Scopus16 WoS17 Europe PMC132015 Harshman, L. C., Wang, X., Nakabayashi, M., Xie, W., Valenca, L., Werner, L., . . . Kantoff, P. W. (2015). Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive prostate cancer. JAMA Oncology, 1(4), 495-504.
Scopus117 WoS108 Europe PMC792015 Sweeney, C. J., Chen, Y. H., Carducci, M., Liu, G., Jarrard, D. F., Eisenberger, M., . . . DiPaola, R. S. (2015). Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. New England Journal of Medicine, 373(8), 737-746.
Scopus2024 WoS1831 Europe PMC11252015 Sharmeen, F., Rosenthal, M. H., Wood, M. J., Tirumani, S. H., Sweeney, C., & Howard, S. A. (2015). Relationship between the pathologic subtype/initial stage and microliths in testicular germ cell tumors. Journal of Ultrasound in Medicine, 34(11), 1977-1982.
Scopus11 WoS10 Europe PMC62015 Bernard, B., & Sweeney, C. J. (2015). Diagnosis and Treatment of Testicular Cancer: A Clinician's Perspective. Surgical Pathology Clinics, 8(4), 717-723.
Scopus7 Europe PMC22015 Sweeney, C., Nakabayashi, M., Regan, M., Xie, W., Hayes, J., Keating, N., . . . Mahal, B. (2015). The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). Journal of the National Cancer Institute, 107(12), djv261-online.
Scopus66 WoS37 Europe PMC332015 Muralidhar, V., Chen, M., Reznor, G., Moran, B., Braccioforte, M., Beard, C., . . . Nguyen, P. (2015). Definition and validation of "favorable high-risk prostate cancer": implications for personalizing treatment of radiation-managed patients. International Journal of Radiation Oncology Biology Physics, 93(4), 828-835.
Scopus40 WoS35 Europe PMC192015 Dinh, K., Mahal, B., Ziehr, D., Muralidhar, V., Chen, Y., Viswanathan, V., . . . Nguyen, P. (2015). Incidence and predictors of upgrading and up staging among 10,000 contemporary patients with low risk prostate cancer. Journal of Urology, 194(2), 343-349.
Scopus99 WoS91 Europe PMC602015 Sweeney, C. J. (2015). The juxtaposition of population science and individual treatment recommendations for intermittent androgen deprivation therapy. JAMA Oncology, 1(9), 1270-1271.
2015 Dinh, K. T., Mahal, B. A. V., Ziehr, D. R., Muralidhar, V., Chen, Y. W., Viswanathan, V. B., . . . Paul, L. N. (2015). Incidence and predictors of upgrading and upstaging among 10,000 contemporary patients with low-risk prostate cancer. JOURNAL OF CLINICAL ONCOLOGY, 33(7), 1 page.
2015 Allemani, C., Weir, H. K., Carreira, H., Harewood, R., Spika, D., Wang, X. S., . . . Ryan, S. (2015). Global surveillance of cancer survival 1995-2009: Analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). The Lancet, 385(9972), 977-1010.
Scopus1856 Europe PMC11692015 Zukotynski, K. A., Kim, C. K., Gerbaudo, V. H., Hainer, J., Taplin, M. -E., Kantoff, P., . . . Sweeney, C. J. (2015). <SUP>18</SUP>F-FDG-PET/CT and <SUP>18</SUP>F-NaF-PET/CT in men with castrate-resistant prostate cancer. AMERICAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 5(1), 72-82.
WoS202014 Voskoboynik, M., Staffurth, J., Malik, Z., Sweeney, C., & Chowdhury, S. (2014). 'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer. Expert Review of Anticancer Therapy, 14(11), 1253-1256.
Scopus11 WoS6 Europe PMC52014 Chiorean, E., Sweeney, C., Youssoufian, H., Qin, A., Dontabhaktuni, A., Loizos, N., . . . Amato, R. (2014). A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 73(3), 595-604.
Scopus57 WoS46 Europe PMC372014 Ravi, P., Gray, K. P., O'Donnell, E. K., & Sweeney, C. J. (2014). Ameta-analysis of patient outcomes with subcentimeter disease after chemotherapy for metastatic non-seminomatous germ cell tumor. Annals of Oncology, 25(2), 331-338.
Scopus32 WoS24 Europe PMC102014 Sharma, J., Gray, K., Evan, C., Nakabayashi, M., Fichorova, R., Rider, J., . . . Sweeney, C. (2014). Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival. The Prostate, 74(3), 225-234.
Scopus32 WoS26 Europe PMC212014 Hahn, N., Yiannoutsos, C., Kirkpatrick, K., Sharma, J., & Sweeney, C. (2014). Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event. Clinical Genitourinary Cancer, 12(1), 33-40.e4.
Scopus8 WoS5 Europe PMC62014 Sun, T., Wang, X., He, H., Sweeney, C., Liu, S., Brown, M., . . . Kantoff, P. (2014). MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A. Oncogene, 33(21), 2790-2800.
Scopus125 WoS112 Europe PMC852014 Mahal, B., Aizer, A., Ziehr, D., Hyatt, A., Lago-Hernandez, C., Chen, Y., . . . Nguyen, P. (2014). The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act. Prostate Cancer and Prostatic Diseases, 17(3), 273-279.
Scopus59 WoS50 Europe PMC332014 Mahal, B., Aizer, A., Ziehr, D., Hyatt, A., Sammon, J., Schmid, M., . . . Nguyen, P. (2014). Trends in disparate treatment of African American men with localized prostate cancer across national comprehensive cancer network risk groups. Urology, 84(2), 386-392.
Scopus73 WoS72 Europe PMC492014 Mahal, B., Ziehr, D., Aizer, A., Hyatt, A., Lago-Hernandez, C., Choueiri, T., . . . Nguyen, P. (2014). Racial disparities in an aging population: the relationship between age and race in the management of African American men with high-risk prostate cancer. Journal of Geriatric Oncology, 5(4), 352-358.
Scopus16 WoS17 Europe PMC122014 Mahal, B., Aizer, A., Ziehr, D., Hyatt, A., Choueiri, T., Hu, J., . . . Nguyen, P. (2014). Racial disparities in prostate cancer - specific mortality in men with low-risk prostate cancer. Clinical Genitourinary Cancer, 12(5), e189-e195.
Scopus40 WoS36 Europe PMC292014 Mahal, B., Ziehr, D., Aizer, A., Hyatt, A., Sammon, J., Schmid, M., . . . Nguyen, P. (2014). Getting back to equal: the influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 32(8), 1285-1291.
Scopus76 WoS70 Europe PMC522014 Choueiri, T., Jacobus, S., Bellmunt, J., Qu, A., Appleman, L., Tretter, C., . . . Rosenberg, J. (2014). Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. Journal of Clinical Oncology, 32(18), 1889-1894.
Scopus219 WoS189 Europe PMC1242014 Hsieh, C., Fei, T., Chen, Y., Li, T., Gao, Y., Wang, X., . . . Kantoff, P. (2014). Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation. Proceedings of the National Academy of Sciences of the United States of America, 111(20), 7319-7324.
Scopus280 WoS260 Europe PMC2282014 Seible, D., Gu, X., Hyatt, A., Beard, C., Choueiri, T., Efstathiou, J., . . . Nguyen, P. (2014). Weight gain on androgen deprivation therapy: which patients are at highest risk?. Urology, 83(6), 1316-1321.
Scopus17 WoS15 Europe PMC92014 Flavin, R., Pettersson, A., Hendrickson, W., Fiorentino, M., Finn, S., Kunz, L., . . . Mucci, L. (2014). SPINK1 protein expression and prostate cancer progression. Clinical Cancer Research, 20(18), 4904-4911.
Scopus61 WoS57 Europe PMC432014 Sharma, J., Gray, K., Harshman, L., Evan, C., Nakabayashi, M., Fichorova, R., . . . Sweeney, C. (2014). Elevated IL-8, TNF-α, and MCP-I in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival. Prostate, 74(8), 820-828.
Scopus68 WoS61 Europe PMC512014 Howard, S., Gray, K., O'Donnell, E., Fennessy, F., Beard, C., & Sweeney, C. (2014). Craniocaudal retroperitoneal node length as a risk factor for relapse from clinical stage I testicular germ cell tumor. American Journal of Roentgenology, 203(4), W415-W420.
Scopus14 WoS13 Europe PMC72014 Smith, M., Sweeney, C., Corn, P., Rathkopf, D., Smith, D., Hussain, M., . . . Scher, H. (2014). Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. Journal of Clinical Oncology, 32(30), 3391-3399.
Scopus109 WoS98 Europe PMC782014 Milowsky, M., Dittrich, C., Durán, I., Jagdev, S., Millard, F., Sweeney, C., . . . Sternberg, C. (2014). Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. European Journal of Cancer, 50(18), 3145-3152.
Scopus95 WoS86 Europe PMC542013 Nakabayashi, M., Hayes, J., Taplin, M., Lefebvre, P., Lafeuille, M., Pomerantz, M., . . . Kantoff, P. (2013). Clinical predictors of survival in men with castration-resistant prostate cancer: Evidence that Gleason score 6 cancer can evolve to lethal disease. Cancer, 119(16), 2990-2998.
Scopus33 WoS29 Europe PMC222013 Sweeney, C. (2013). Prostate cancer therapy: Going forwards by going backwards. The Lancet Oncology, 14(2), 104-105.
Scopus3 WoS3 Europe PMC52013 Nichols, C. R., Roth, B., Albers, P., Einhorn, L. H., Foster, R., Daneshmand, S., . . . Kollmannsberger, C. (2013). Active surveillance is the preferred approach to clinical stage i testicular cancer. Journal of Clinical Oncology, 31(28), 3490-3493.
Scopus121 WoS106 Europe PMC622013 Valencia, P., Pridgen, E., Perea, B., Gadde, S., Sweeney, C., Kantoff, P., . . . Farokhzad, O. (2013). Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles. Nanomedicine, 8(5), 687-698.
Scopus67 WoS61 Europe PMC372013 Smith, D., Smith, M., Sweeney, C., Elfiky, A., Logothetis, C., Corn, P., . . . Hussain, M. (2013). Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. Journal of Clinical Oncology, 31(4), 412-419.
Scopus376 WoS345 Europe PMC2722013 Nguyen, P., Devlin, P., Beard, C., Orio, P., O'Leary, M., Wolfsberger, L., . . . Hatiboglu, G. (2013). High-dose-rate brachytherapy for prostate cancer in a previously radiated patient with polyethylene glycol hydrogel spacing to reduce rectal dose: Case report and review of the literature. Brachytherapy, 12(1), 77-83.
Scopus22 Europe PMC162013 Sweeney, C. J. (2013). Preface. Hematology/Oncology Clinics of North America, 27(6), 11-12.
2012 Hrkach, J., Von Hoff, D., Ali, M., Andrianova, E., Auer, J., Campbell, T., . . . Zale, S. (2012). Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Science Translational Medicine, 4(128), 128ra39-1-128ra39-11.
Scopus955 WoS900 Europe PMC3962012 Pettersson, A., Graff, R., Bauer, S., Pitt, M., Lis, R., Stack, E., . . . Mucci, L. (2012). The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: A cohort study and meta-analysis. Cancer Epidemiology Biomarkers and Prevention, 21(9), 1497-1509.
Scopus266 WoS249 Europe PMC1922012 Arvold, N. D., Catalano, P. J., Sweeney, C. J., Hoffman, K. E., Nguyen, P. L., Balboni, T. A., . . . Beard, C. J. (2012). Barriers to the implementation of surveillance for Stage I testicular seminoma. International Journal of Radiation Oncology Biology Physics, 84(2), 383-389.
Scopus19 WoS16 Europe PMC132012 Patel, Y., Carr, K., Magjuka, D., Mohammadi, Y., Dropcho, E., Reed, A., . . . Hahn, N. (2012). Successful recruitment of healthy African American men to genomic studies from high-volume community health fairs: implications for future genomic research in minority populations. Cancer, 118(4), 1075-1082.
Scopus8 WoS7 Europe PMC82012 Millward, M., Price, T., Townsend, A., Sweeney, C., Spencer, A., Sukumaran, S., . . . Spear, M. (2012). Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Investigational New Drugs, 30(6), 2303-2317.
Scopus122 WoS111 Europe PMC792012 Sharma, J., Gray, K. P., Nakabayashi, M., Petrozziello, G., Evan, C., Fichorova, R., . . . Sweeney, C. (2012). Use of elevated insulin-like growth factor binding protein-1 (IGFBP-1) to predict outcomes in men with metastatic prostate cancer treated with androgen-deprivation therapy (ADT).. JOURNAL OF CLINICAL ONCOLOGY, 30(5), 1 page.
2012 Hutson, T. E., Dang, L. H., Lauer, R. C., Starodub, A., Hauke, R. J., Logan, T., . . . Sarantopoulos, J. (2012). Phase I/II study of a BNC105P/everolimus regimen for progressive metastatic renal cell carcinoma (mRCC) following prior tyrosine kinase inhibitors (Hoosier Oncology Group).. JOURNAL OF CLINICAL ONCOLOGY, 30(5), 1 page.
WoS12012 Sharma, J., Gray, K. P., Nakabayashi, M., Petrozziello, G., Evan, C., Fichorova, R., . . . Sweeney, C. (2012). Use of elevated baseline IL-8, CCL-2, and TNFα to predict for shorter overall survival (OS) in men with metastatic prostate cancer initiating androgen-deprivation therapy (ADT). JOURNAL OF CLINICAL ONCOLOGY, 30(5), 1 page.
2012 Rudman, S. M., Gray, K. P., Kasperzyk, J., Pitt, M., Giovannucci, E., Loda, M., . . . Sweeney, C. (2012). Association of metabolic syndrome with reduced survival among men receiving androgen deprivation therapy for nonmetastatic prostate cancer. JOURNAL OF CLINICAL ONCOLOGY, 30(5), 1 page.
WoS32012 Rudman, S. M., Gray, K. P., Kasperzyk, J., Pitt, M., Giovannucci, E., Loda, M., . . . Sweeney, C. (2012). Association of metabolic syndrome with reduced survival among men receiving androgen deprivation therapy for nonmetastatic prostate cancer.. J Clin Oncol, 30(5_suppl), 56. 2012 Sharma, J., Gray, K. P., Nakabayashi, M., Petrozziello, G., Evan, C., Fichorova, R., . . . Sweeney, C. (2012). Use of elevated baseline IL-8, CCL-2, and TNFα to predict for shorter overall survival (OS) in men with metastatic prostate cancer initiating androgen-deprivation therapy (ADT).. J Clin Oncol, 30(5_suppl), 13. 2011 Smith, D. C., Smith, M. R., Small, E. J., Sweeney, C., Kurzrock, R., Gordon, M. S., . . . Hussain, M. (2011). Phase II study of XL184 in a cohort of patients (pts) with castration-resistant prostate cancer (CRPC) and measurable soft tissue disease. JOURNAL OF CLINICAL ONCOLOGY, 29(7), 1 page.
WoS22011 Hahn, N. M., Jung, J., Philips, S., Patel, Y. R., Carr, K. A., Mohammadi, Y., . . . Skaar, T. C. (2011). Use of germ-line single nucleotide polymorphisms (SNPs) in drug transporters (ABCG2/ABCB1) and tubulin (TUBB4) to predict survival in patients with metastatic castrate-resistant prostate cancer (CRPC) receiving docetaxel. JOURNAL OF CLINICAL ONCOLOGY, 29(7), 2 pages.
2011 Davis, T. L., Jung, J., Carr, K. A., Philips, S., Mohammadi, Y., Campbell, M. T., . . . Hahn, N. M. (2011). Androgen pathway constitutional polymorphism predictors of progression-free and overall survivals in advanced castrate-resistant prostate cancer (CRPC) patients treated with ketoconazole (KC). JOURNAL OF CLINICAL ONCOLOGY, 29(7), 1 page.
2011 Arvold, N. D., Catalano, P. J., Sweeney, C., Hoffman, K. E., Nguyen, P. L., Balboni, T. A., . . . Beard, C. (2011). Physician and patient factors influencing management recommendations in stage I testicular seminoma: A survey among radiation oncologists in the United States. JOURNAL OF CLINICAL ONCOLOGY, 29(7), 1 page.
2011 Guancial, E. A., Rosenberg, J. E., & Sweeney, C. J. (2011). Update in Urothelial Carcinoma: Novel Agents and Targeted Therapy.. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2011, 171-176. 2011 Arvold, N. D., Catalano, P. J., Sweeney, C., Hoffman, K. E., Nguyen, P. L., Balboni, T. A., . . . Beard, C. (2011). Physician and patient factors influencing management recommendations in stage I testicular seminoma: A survey among radiation oncologists in the United States.. J Clin Oncol, 29(7_suppl), 225. 2011 Smith, D. C., Smith, M. R., Small, E. J., Sweeney, C., Kurzrock, R., Gordon, M. S., . . . Hussain, M. (2011). Phase II study of XL184 in a cohort of patients (pts) with castration-resistant prostate cancer (CRPC) and measurable soft tissue disease.. J Clin Oncol, 29(7_suppl), 127. 2011 Davis, T. L., Jung, J., Carr, K. A., Philips, S., Mohammadi, Y., Campbell, M. T., . . . Hahn, N. M. (2011). Androgen pathway constitutional polymorphism predictors of progression-free and overall survivals in advanced castrate-resistant prostate cancer (CRPC) patients treated with ketoconazole (KC).. J Clin Oncol, 29(7_suppl), 54. 2011 Campbell, M. T., Jung, J., Philips, S., Mohammadi, Y., Carr, K. A., Davis, T. L., . . . Hahn, N. M. (2011). Germ-line single nucleotide polymorphism (SNP) predictors of progression-free survival and overall survival in patients with advanced prostate cancer treated with androgen-deprivation therapy (ADT).. JOURNAL OF CLINICAL ONCOLOGY, 29(7), 1 page.
2011 Hutson, T. E., Sarantopoulos, J., Logan, T., Sonpavde, G., Galsky, M. D., Sweeney, C., . . . Hahn, N. M. (2011). Phase I/II study of BNC105P in combination with everolimus or following everolimus for progressive metastatic renal cell carcinoma following prior tyrosine kinase inhibitors.. JOURNAL OF CLINICAL ONCOLOGY, 29(15), 1 page.
2011 Shanmugam, R., Kusumanchi, P., Appaiah, H., Cheng, L., Crooks, P., Neelakantan, S., . . . Sweeney, C. (2011). A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NF-κB and generating reactive oxygen species. International Journal of Cancer, 128(10), 2481-2494.
Scopus66 WoS65 Europe PMC432011 Resta, L., Pili, R., Eisenberger, M., Spitz, A., King, S., Porter, J., . . . Sweeney, C. (2011). A Phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone. Cancer Chemotherapy and Pharmacology, 67(2), 431-438.
Scopus1 Europe PMC12011 Hussain, M., Smith, M. R., Sweeney, C., Corn, P. G., Elfiky, A., Gordon, M. S., . . . Smith, D. C. (2011). Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.. JOURNAL OF CLINICAL ONCOLOGY, 29(15), 1 page.
WoS372011 Hahn, N. M., Jung, J., Dantzer, J., Philips, S., Patel, Y. R., Carr, K. A., . . . Skaar, T. C. (2011). A case-control study examining associations of germ-line oxidative DNA repair single-nucleotide polymorphisms (SNPs) with lethal prostate cancer (PCa) risk.. JOURNAL OF CLINICAL ONCOLOGY, 29(15), 1 page.
2011 Sharma, J., Yiannoutsos, C. T., Hahn, N. M., & Sweeney, C. (2011). Prognositic value of suppressed markers of bone turnover (BTO) after 6 months of androgen deprivation therapy (ADT) in prostate cancer.. JOURNAL OF CLINICAL ONCOLOGY, 29(15), 1 page.
WoS32011 Okera, M., Bae, K., Bernstein, E., Cheng, L., Lawton, C., Wolkov, H., . . . Sweeney, C. (2011). Evaluation of nuclear factor κB and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610. BJU International, 108(2B Sp Iss), E51-E58.
Scopus17 WoS18 Europe PMC152011 Hahn, N., Stadler, W., Zon, R., Waterhouse, D., Picus, J., Nattam, S., . . . Sweeney, C. (2011). Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier oncology group GU 04-75. Journal of Clinical Oncology, 29(12), 1525-1530.
Scopus173 WoS159 Europe PMC1032011 Harrison, M., Hahn, N., Pili, R., Oh, W., Hammers, H., Sweeney, C., . . . Liu, G. (2011). A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal <sup>®</sup> dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Investigational New Drugs, 29(6), 1465-1474.
Scopus98 WoS89 Europe PMC552011 Estabrook, N., Chin-Sinex, H., Borgmann, A., Dhaemers, R., Shapiro, R., Gilley, D., . . . Mendonca, M. (2011). Inhibition of NF-κB and DNA double-strand break repair by DMAPT sensitizes non-small-cell lung cancers to X-rays. Free Radical Biology and Medicine, 51(12), 2249-2258.
Scopus25 WoS27 Europe PMC192011 Jonker, D., Rosen, L., Sawyer, M., de Braud, F., Wilding, G., Sweeney, C., . . . Galbraith, S. (2011). A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. Annals of Oncology, 22(6), 1413-1419.
Scopus72 WoS67 Europe PMC442011 Tolcher, A., Sweeney, C., Papadopoulos, K., Patnaik, A., Chiorean, E., Mita, A., . . . Mita, M. (2011). Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin. Clinical Cancer Research, 17(2), 363-371.
Scopus88 Europe PMC572011 Chang, P., Szymanski, K., Dunn, R., Chipman, J., Litwin, M., Nguyen, P., . . . Sanda, M. (2011). Expanded prostate cancer index composite for clinical practice: Development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. Journal of Urology, 186(3), 865-872.
Scopus139 WoS125 Europe PMC882011 Flanagan, J., Gray, P., Hahn, N., Hayes, J., Myers, L., Carney-Doebbeling, C., & Sweeney, C. (2011). Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer. Annals of Oncology, 22(4), 801-807.
Scopus57 WoS50 Europe PMC412010 Shanmugam, R., Kusumanchi, P., Cheng, L., Crooks, P., Neelakantan, S., Matthews, W., . . . Sweeney, C. J. (2010). A water-soluble parthenolide analogue suppresses in vivo prostate cancer growth by targeting NFκB and generating reactive oxygen species. Prostate, 70(10), 1074-1086.
Scopus62 WoS57 Europe PMC482010 Sweeney, C. J., Takimoto, C., Wood, L., Porter, J. M., Tracewell, W. G., Darwish, M., . . . Remick, S. C. (2010). A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment. Cancer Chemotherapy and Pharmacology, 66(2), 345-356.
Scopus29 WoS25 Europe PMC192010 Sweeney, C. J., Chiorean, E. G., Verschraegen, C. F., Lee, F. C., Jones, S., Royce, M., . . . Burris, H. A. (2010). A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors. Journal of Clinical Oncology, 28(29), 4513-4520.
Scopus41 WoS35 Europe PMC272010 Chiorean, E. G., Malireddy, S., Younger, A. E., Jones, D. R., Waddell, M. J., Sloop, M. I., . . . Sweeney, C. J. (2010). A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 66(3), 441-448.
Scopus8 WoS7 Europe PMC62010 Heath, E. I., Chiorean, E. G., Sweeney, C. J., Hodge, J. P., Lager, J. J., Forman, K., . . . Lorusso, P. (2010). A phase i study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors. Clinical Pharmacology and Therapeutics, 88(6), 818-823.
Scopus88 WoS79 Europe PMC612010 Hayes, J. H., Ollendorf, D. A., Pearson, S. D., Barry, M. J., Kantoff, P. W., Stewart, S. T., . . . McMahon, P. M. (2010). Active surveillance compared with initial treatment for men with low-risk prostate cancer: A decision analysis. JAMA, 304(21), 2373-2380.
Scopus218 WoS197 Europe PMC1502010 Hahn, N. M., Stadler, W. M., Zon, R., Waterhouse, D. M., Picus, J., Nattam, S. R., . . . Sweeney, C. (2010). Mature results from Hoosier Oncology Group GU04-75 phase II trial of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC). JOURNAL OF CLINICAL ONCOLOGY, 28(15), 1 page.
WoS42010 Shamash, J., Stebbing, J., Sweeney, C., Sonpavde, G., Harland, S., Dawkins, G., . . . Powles, T. (2010). A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrate-resistant prostate cancer. Cancer, 116(15), 3595-3602.
Scopus19 WoS20 Europe PMC142010 Rosen, P. J., Sweeney, C. J., Park, D. J., Beaupre, D. M., Deng, H., Leitch, I. M., . . . Yee, L. K. (2010). A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors. Clinical Cancer Research, 16(9), 2677-2687.
Scopus64 Europe PMC472010 Gordon, M. S., Sweeney, C. S., Mendelson, D. S., Eckhardt, S. G., Anderson, A., Beaupre, D. M., . . . Gore, L. (2010). Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clinical Cancer Research, 16(2), 699-710.
Scopus151 Europe PMC1072010 Sweeney, C., Dugan, W. M., Dreicer, R., Chu, F., Parks, G., Baker, K., . . . Yiannoutsos, C. T. (2010). A randomized placebo-controlled trial of daily high-dose oral risedronate in men with metastatic prostate cancer commencing androgen deprivation therapy (ADT). JOURNAL OF CLINICAL ONCOLOGY, 28(15), 1 page.
WoS192010 Chiorean, E. G., Matei, D., Younger, A., Funke, J. M., Waddell, M. J., Jones, D. R., . . . Sweeney, C. (2010). Phase I study of sorafenib (S) with bevacizumab (B) and paclitaxel (P) in patients (pts) with refractory solid tumors.. JOURNAL OF CLINICAL ONCOLOGY, 28(15), 1 page.
WoS12009 Shanmugam, R., Wei, Z., Crooks, P., Nakshatri, H., & Sweeney, C. (2009). Dimethylaminoparthenolide targets apoptotic machinery in glioblastoma through ROS generation and NF\#954;B inhibition. CANCER RESEARCH, 69, 1 page. 2009 Mendonca, M., Estabrook, N., Watson, C., Miller, D., Chin-Sinex, H., Borgman, A., . . . Sweeney, C. (2009). The parthenolide analog DMAPT induces X-ray sensitization of radiation resistant lung cancer cells through inhibition of NF-\#954;B dependent split dose recovery and DNA double strand break repair. CANCER RESEARCH, 69, 2 pages. 2009 Kadlubar, S., Anderson, J. P., Sweeney, C., Gross, M. D., Lang, N. P., Kadlubar, F. F., & Anderson, K. E. (2009). Phenotypic CYP2A6 variation and the risk of pancreatic cancer. Journal of the Pancreas, 10(3), 263-270.
Scopus25 WoS22 Europe PMC192009 Watson, C., Miller, D. A., Chin-Sinex, H., Losch, A., Hughes, W., Sweeney, C., & Mendonca, M. S. (2009). Suppression of NF-κB activity by parthenolide induces x-ray sensitivity through inhibition of split-dose repair in TP53 null prostate cancer Cells. Radiation Research, 171(4), 389-396.
Scopus27 WoS25 Europe PMC142009 Hahn, N., Zon, R., Yu, M., Ademuyiwa, F., Jones, T., Dugan, W., . . . Sweeney, C. (2009). A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67. Annals of Oncology, 20(12), 1971-1976.
Scopus18 WoS15 Europe PMC122009 Gardiner, R., Sweeney, C., & Tilley, W. (2009). Testosterone Therapy in Castrate-Resistant Prostate Cancer: A Possible New Approach. European Urology, 56(2), 245-246.
Scopus8 WoS7 Europe PMC62009 Hahn, N., Powles, T., & Sweeney, C. (2009). Development of novel agents for bladder cancer. Update on Cancer Therapeutics, 3(4), 160-169.
2009 Hahn, N., Reckova, M., Cheng, L., Baldridge, L., Cummings, O., & Sweeney, C. (2009). Patient With Malignant Paraganglioma Responding to the Multikinase Inhibitor Sunitinib Malate. Journal of Clinical Oncology, 27(3), 460-463.
Scopus35 WoS34 Europe PMC302009 Clarke, S. J., Smith, J. T., Gebbie, C., Sweeney, C., & Olszewski, N. (2009). A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer.. J Clin Oncol, 27(15_suppl), 3025. 2009 Hahn, N. M., Stadler, W. M., Zon, R. T., Waterhouse, D. M., Picus, J., Nattam, S. R., . . . Sweeney, C. J. (2009). A multicenter phase II study of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC): Hoosier Oncology Group GU-0475.. J Clin Oncol, 27(15_suppl), 5018. 2008 Chiorean, E., Porter, J., Foster, A., Al Omari, A., Yoder, C., Fife, K., . . . Sweeney, C. (2008). A phase 1 and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies. Clinical Cancer Research, 14(4), 1131-1137.
Scopus21 WoS20 Europe PMC152008 Carpenter, J., Rawl, S., Porter, J., Schmidt, K., Tornatta, J., Ojewole, F., . . . Giesler, R. (2008). Oncology Outpatient and Provider Responses to a Computerized Symptom Assessment System. Oncology Nursing Forum, 35(4), 661-669.
Scopus24 WoS20 Europe PMC172008 Strother, M., & Sweeney, C. (2008). Lessons learned from development of docetaxel. Expert Opinion on Drug Metabolism & Toxicology, 4(7), 1007-1019.
Scopus5 WoS4 Europe PMC22008 Sonpavde, G., Ross, R., Powles, T., Sweeney, C. J., Hahn, N., Hutson, T. E., . . . Sternberg, C. N. (2008). Novel agents for muscle-invasive and advanced urothelial cancer. BJU International, 101(8), 937-943.
Scopus13 WoS7 Europe PMC62008 Yip-Schneider, M. T., Wu, H., Njoku, V., Ralstin, M., Holcomb, B., Crooks, P. A., . . . Schmidt, C. M. (2008). Effect of celecoxib and the novel anti-cancer agent, dimethylamino- parthenolide, in a developmental model of pancreatic cancer. Pancreas, 37(3), e45-e53.
Scopus30 Europe PMC182008 Li, L., Yu, M., Jason, R. D., Shen, C., Azzouz, F., McLeod, H. L., . . . Flockhart, D. A. (2008). A mixture model approach in gene-gene and gene-environmental interactions for binary phenotypes. Journal of Biopharmaceutical Statistics, 18(6), 1150-1177.
Scopus3 WoS4 Europe PMC42008 Hahn, N. M., Zon, R. T., Jones, T., Ademuyiwa, F., Dugan, W. M., Whalen, C., . . . Sweeney, C. J. (2008). A multicenter phase II study of pemetrexed as second-line chemotherapy for the treatment of hormone refractory prostate cancer (HRPC); Hoosier Oncology Group GU-0367. JOURNAL OF CLINICAL ONCOLOGY, 26(15), 1 page.
WoS22008 Chiorean, E. G., Sweeney, C. J., Verschraegen, C. F., Lee, F. C., Jones, S. F., Rabinowitz, I., . . . Burris, H. A. (2008). Tolerability/safety of sunitinib (SU) on schedule 2/1 in combination with capecitabine (C) in patients (pts) with advanced solid tumors (STs): A phase I dose-finding study. JOURNAL OF CLINICAL ONCOLOGY, 26(15), 1 page.
WoS12008 Malireddy, S. R., Chiorean, E. G., Younger, A., Jones, D., Waddell, M., Margol, M., . . . Sweeney, C. J. (2008). A phase I dose escalation trial of the VEGFR tyrosine kinase inhibitor, PTK787/ZK222584 (PTK/ZK), used in combination with paclitaxel in patients with advanced solid tumors with pharmacokinetic (PK) analysis. JOURNAL OF CLINICAL ONCOLOGY, 26(15), 1 page.
2008 Harrison, M. R., Hahn, N., Pili, R., Oh, W. K., Kim, K., Wilding, G., . . . Liu, G. (2008). Phase II study of 2-methoxyestradiol (2ME2) NanoCrystal Dispersion (NCD) in patients with taxane-refractory, metastatic hormone-refractory prostate cancer (HRPC). JOURNAL OF CLINICAL ONCOLOGY, 26(15), 1 page.
WoS12008 Schwertschlag, U. S., Chiorean, E. G., Anthony, S. P., Sweeney, C. J., Borad, M. J., Von Hoff, D. D., . . . Ramanathan, R. K. (2008). Phase 1 pharmacokinetic (PK) and pharmacodynamic(PD) evaluation of SF1126 a vascular targeted pan phosphoinositide 3-kinase (PI3K) inhibitor in patients with solid tumors. JOURNAL OF CLINICAL ONCOLOGY, 26(15), 1 page.
WoS92008 Youssoufian, H., Amato, R. J., Sweeney, C. J., Chiorean, E. G., Fox, F., Katz, T., & Rowinsky, E. K. (2008). Phase 1 study of IMC-3G3, an IgG1 monoclonal antibody targeting PDGFRα in patients with advanced solid malignancies. JOURNAL OF CLINICAL ONCOLOGY, 26(15), 1 page.
WoS42008 Sweeney, C. J., Chriorean, E. G., Mita, M. M., Papadopoulos, K. P., Silver, B., Freed, M., . . . Tolcher, A. W. (2008). Phase I study of CT-322, first Adnectin protein therapeutic and potent inhibitor of VEGFR-2, in patients (pts) with advanced solid tumors (ST). JOURNAL OF CLINICAL ONCOLOGY, 26(15), 1 page.
WoS72008 Rosen, P. J., Sweeney, C. J., Park, D. J., Rasmussen, E., Shubhakar, P., Scripture, C., . . . Yee, L. K. (2008). AMG 102, an HGF/SF antagonist, in combination with anti-angiogenesis targeted therapies in adult patients with advanced solid tumors. JOURNAL OF CLINICAL ONCOLOGY, 26(15), 1 page.
WoS102008 Strother, R. M., Jones, D., Li, L., Younger, A., Einhorn, L. H., Williams, S., & Sweeney, C. J. (2008). Effect of the C3435T genetic polymorphism in MDR1 on etoposide pharmacokinetics. JOURNAL OF CLINICAL ONCOLOGY, 26(15), 1 page.
WoS12007 Vegeler, R. C., Yip-Schneider, M. T., Ralstin, M., Wu, H., Crooks, P. A., Neelakantan, S., . . . Schmidt, C. M. (2007). Effect of Celecoxib and Novel Agent LC-1 in a Hamster Model of Lung Cancer. Journal of Surgical Research, 143(1), 169-176.
Scopus5 Europe PMC42007 Yip-Schneider, M. T., Wu, H., Ralstin, M., Yiannoutsos, C., Crooks, P. A., Neelakantan, S., . . . Schmidt, C. M. (2007). Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo. Molecular Cancer Therapeutics, 6(6), 1736-1744.
Scopus42 Europe PMC292007 Masters, A. R., Sweeney, C. J., & Jones, D. R. (2007). The quantification of erlotinib (OSI-774) and OSI-420 in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 848(2), 379-383.
Scopus45 Europe PMC222007 Hahn, N. M., Kelley, M. R., Klaunig, J. E., Koch, M. O., Li, L., & Sweeney, C. J. (2007). Constitutional polymorphisms of prostate cancer: Prognostic and diagnostic implications. Future Oncology, 3(6), 665-682.
Scopus1 Europe PMC12007 Mendonca, M. S., Chin-Sinex, H., Gomez-Millan, J., Datzman, N., Hardacre, M., Comerford, K., . . . Sweeney, C. (2007). Parthenolide sensitizes cells to X-ray-induced cell killing through inhibition of NF-κB and split-dose repair. Radiation Research, 168(6), 689-697.
Scopus36 Europe PMC262007 Guzman, M. L., Rossi, R. M., Neelakantan, S., Li, X., Corbett, C. A., Hassane, D. C., . . . Jordan, C. T. (2007). An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood, 110(13), 4427-4435.
Scopus352 Europe PMC2402007 Kyselova, Z., Mechref, Y., Al Bataineh, M. M., Dobrolecki, L. E., Hickey, R. J., Vinson, J., . . . Novotny, M. V. (2007). Alterations in the serum glycome due to metastatic prostate cancer. Journal of Proteome Research, 6(5), 1822-1832.
Scopus208 Europe PMC1452007 Schneider, B., Fukunaga, A., Murry, D., Yoder, C., Fife, K., Foster, A., . . . Sweeney, C. (2007). A phase I, pharmacokinetic and pharmacodynamic dose escalation trial of weekly paclitaxel with interferon-α2b in patients with solid tumors. Cancer Chemotherapy and Pharmacology, 59(2), 261-268.
Scopus8 Europe PMC52007 Yip-Schneider, M. T., Wu, H., Ralstin, M., Yiannoutsos, C., Crooks, P. A., Neelakantan, S., . . . Schmidt, C. M. (2007). Erratum: Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo (Molecular Cancer Therapeutics (2007) 6, (1736-1744)). Molecular Cancer Therapeutics, 6(10), 2816.
2007 Sonpavde, G., Chi, K. N., Powles, T., Sweeney, C. J., Hahn, N., Hutson, T. E., . . . Kadmon, D. (2007). Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. Cancer, 110(12), 2628-2639.
Scopus17 Europe PMC142007 Agus, D. B., Sweeney, C. J., Morris, M. J., Mendelson, D. S., McNeel, D. G., Ahmann, F. R., . . . Scher, H. I. (2007). Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. Journal of Clinical Oncology, 25(6), 675-681.
Scopus89 Europe PMC512006 Vaughn, D. J., Powell, M., Catalano, P. J., Loehrer, P., Nichols, C., Sweeney, C., . . . Dipaola, R. S. (2006). The influence of body mass index (BMI) on outcome in patients with advanced germ cell tumors (GCT).. J Clin Oncol, 24(18_suppl), 14594. 2006 Sweeney, C. J., Roth, B. J., Kabbinavar, F. F., Vaughn, D. J., Arning, M., Curiel, R. E., . . . Kaufman, D. S. (2006). Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. Journal of Clinical Oncology, 24(21), 3451-3457.
Scopus211 WoS186 Europe PMC1532006 Sweeney, C. J., Takimoto, C. H., Latz, J. E., Baker, S. D., Murry, D. J., Krull, J. H., . . . Rowinsky, E. K. (2006). Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or ibuprofen in patients with advanced cancer. Clinical Cancer Research, 12(2), 536-542.
Scopus36 Europe PMC182006 Mita, A. C., Sweeney, C. J., Baker, S. D., Goetz, A., Hammond, L. A., Patnaik, A., . . . Takimoto, C. H. (2006). Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. Journal of Clinical Oncology, 24(4), 552-562.
Scopus106 Europe PMC542006 Sweeney, C. (2006). The Case for Systemic Therapy Alone for Prostate Cancer. Journal of Urology, 176(6 SUPPL.), S42-S46.
Scopus1 Europe PMC12006 Shanmugam, R., Jayaprakasan, V., Gokmen-Polar, Y., Kelich, S., Miller, K. D., Yip-Schneider, M., . . . Sweeney, C. J. (2006). Restoring chemotherapy and hormonetherapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model. Prostate, 66(14), 1498-1511.
Scopus51 Europe PMC272006 Gray, R., Manola, J., Saxman, S., Wright, J., Dutcher, J., Atkins, M., . . . DiPaola, R. S. (2006). Phase II clinical trial design: Methods in translational research from the genitourinary committee at the Eastern Cooperative Oncology Group. Clinical Cancer Research, 12(7 I), 1966-1969.
Scopus26 WoS23 Europe PMC172006 Hahn, N. M., Marsh, S., Fisher, W., Langdon, R., Zon, R., Browning, M., . . . Sweeney, C. J. (2006). Hoosier oncology group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis. Clinical Cancer Research, 12(20 PART 1), 6094-6099.
Scopus56 Europe PMC412006 Sweeney, C. J. (2006). ECOG 3805: CHAARTED - ChemoHormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer. Clinical Advances in Hematology and Oncology, 4(8), 588-589.
Scopus15 Europe PMC132005 Pan, C. X., Loehrer, P., Seitz, D., Helft, P., Juliar, B., Ansari, R., . . . Sweeney, C. (2005). A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer. Oncology, 69(1), 63-70.
Scopus30 Europe PMC212005 Li, J., Juliar, B., Yiannoutsos, C., Ansari, R., Fox, E., Fisch, M. J., . . . Sweeney, C. J. (2005). Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: A phase II Hoosier Oncology Group study. Journal of Clinical Oncology, 23(6), 1185-1191.
Scopus90 Europe PMC602005 Miller, K. D., Sweeney, C. J., & Sledge, G. W. (2005). Can tumor angiogenesis be inhibited without resistance?. EXS, (94), 95-112.
Scopus65 Europe PMC312005 Sweeney, C., Liu, G., Yiannoutsos, C., Kolesar, J., Horvath, D., Staab, M. J., . . . Wilding, G. (2005). A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clinical Cancer Research, 11(18), 6625-6633.
Scopus159 Europe PMC1092005 Li, J., Juliar, B., Yiannoutsos, C., Ansari, R., Fox, E., Fisch, M. J., . . . Trump, D. L. (2005). Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: A phase II Hoosier Oncology Group study. Urologic Oncology: Seminars and Original Investigations, 23(5), 382.
Scopus12005 Hahn, N. M., & Sweeney, C. J. (2005). Germ cell tumors: An update of recent data and review of active protocols in stage I and metastatic disease. Urologic Oncology: Seminars and Original Investigations, 23(4), 293-302.
Scopus7 Europe PMC22005 Sweeney, C. J., Mehrotra, S., Sadaria, M. R., Kumar, S., Shortle, N. H., Roman, Y., . . . Nakshatri, H. (2005). The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. Molecular Cancer Therapeutics, 4(6), 1004-1012.
Scopus148 Europe PMC902005 Yip-Schneider, M. T., Nakshatri, H., Sweeney, C. J., Marshall, M. S., Wiebke, E. A., & Schmidt, C. M. (2005). Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-κB pathway in pancreatic carcinoma cells. Molecular Cancer Therapeutics, 4(4), 587-594.
Scopus111 Europe PMC772004 Sweeney, C., Li, L., Shanmugam, R., Bhat-Nakshatri, P., Jayaprakasan, V., Baldridge, L. A., . . . Cheng, L. (2004). Nuclear factor-κB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clinical Cancer Research, 10(16), 5501-5507.
Scopus156 Europe PMC1102004 Cheng, L., Zhang, S., Sweeney, C. J., Kao, C., Gardner, T. A., & Eble, J. N. (2004). Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model. Anticancer Research, 24(4), 2135-2140.
Scopus34 Europe PMC202004 Pan, C. X., Kinch, M. S., Kiener, P. A., Langermann, S., Serrero, G., Sun, L., . . . Cheng, L. (2004). PC Cell-Derived Growth Factor Expression in Prostatic Intraepithelial Neoplasia and Prostatic Adenocarcinoma. Clinical Cancer Research, 10(4), 1333-1337.
Scopus64 Europe PMC472004 Sandler, A., Gordon, M., De Alwis, D. P., Pouliquen, I., Green, L., Marder, P., . . . Slapak, C. A. (2004). A phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. Clinical Cancer Research, 10(10), 3265-3272.
Scopus103 Europe PMC592004 Curry, E. A., Murry, D. J., Yoder, C., Fife, K., Armstrong, V., Nakshatri, H., . . . Sweeney, C. J. (2004). Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Investigational New Drugs, 22(3), 299-305.
Scopus110 Europe PMC632004 Kaufman, H. L., Wang, W., Manola, J., DiPaola, R. S., Ko, Y. J., Sweeney, C., . . . Weiner, L. M. (2004). Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): A trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 22(11), 2122-2132.
Scopus226 WoS198 Europe PMC1562003 Madani, A., Kemmer, K., Sweeney, C., Corless, C., Ulbright, T., Heinrich, M., & Einhorn, L. (2003). Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors. Annals of Oncology, 14(6), 873-880.
Scopus56 Europe PMC302003 Miller, K. D., Sweeney, C. J., & Sledge, G. W. (2003). The Snark is a Boojum: The continuing problem of drug resistance in the antiangiogenic era. Annals of Oncology, 14(1), 20-28.
Scopus44 Europe PMC182003 Sweeney, C. J., Miller, K. D., & Sledge, G. W. (2003). Resistance in the anti-angiogenic era: Nay-saying or a word of caution?. Trends in Molecular Medicine, 9(1), 24-29.
Scopus45 Europe PMC222003 Hanna, N., Sweeney, C., Fife, K., Dropcho, S., & Seitz, D. E. (2003). Phase I trial of carboplatin and paclitaxel with escalating doses of oral topotecan in patients with solid tumors. American Journal of Clinical Oncology: Cancer Clinical Trials, 26(2), 200-202.
Scopus3 Europe PMC22003 Paterson, R. F., Ulbright, T. M., MacLennan, G. T., Zhang, S., Pan, C. X., Sweeney, C. J., . . . Cheng, L. (2003). Molecular Genetic Alterations in the Laser-Capture-Microdissected Stroma Adjacent to Bladder Carcinoma. Cancer, 98(9), 1830-1836.
Scopus88 Europe PMC642003 Brandli, D. W., Ulbright, T. M., Foster, R. S., Cummings, O. W., Zhang, S., Sweeney, C. J., . . . Cheng, L. (2003). Stroma adjacent to metastatic mature teratoma after chemotherapy for testicular germ cell tumors is derived from the same progenitor cells as the teratoma. Cancer Research, 63(18), 6063-6068.
Scopus46 Europe PMC292002 Sanchez, K. M., Sweeney, C. J., Mass, R., Koch, M. O., Eckert, G. J., Geary, W. A., . . . Cheng, L. (2002). Evaluation of HER-2/neu expression in prostatic adenocarcinoma: A request for a standardized, organ specific methodology. Cancer, 95(8), 1650-1655.
Scopus45 Europe PMC272002 Zhang, S., Zeng, G., Kao, C., Gardner, T., Sweeney, C., Yang, N. S., . . . Cheng, L. (2002). Fas-Fas ligand signaling pathway mediates an interleukin-12-induced rejection of a murine prostate tumor system. Prostate, 53(1), 69-76.
Scopus8 Europe PMC52002 Curry, E. A., & Sweeney, C. J. (2002). Resistance to luteinizing hormone releasing hormone agonist therapy for metastatic prostate cancer. Journal of Urology, 168(1), 193.
Scopus13 Europe PMC52002 Bhat-Nakshatri, P., Sweeney, C. J., & Nakshatri, H. (2002). Identification of signal transduction pathways involved in constitutive NF-kB activation in breast cancer cells. Oncogene, 21(13), 2066-2078.
Scopus109 Europe PMC652002 Sweeney, C. J., Monaco, F. J., Jung, S. H., Wasielewski, M. J., Picus, J., Ansari, R. H., . . . Einhorn, L. H. (2002). A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer. Annals of Oncology, 13(3), 435-440.
Scopus30 Europe PMC182002 Sweeney, C. J., Marshall, M. S., Barnard, D. S., Heilman, D. K., Billings, S. D., Cheng, L., . . . Yip-Schneider, M. T. (2002). Cyclo-oxygenase-2 expression in primary cancers of the lung and bladder compared to normal adjacent tissue. Cancer Detection and Prevention, 26(3), 238-244.
Scopus19 Europe PMC102002 Cheng, L., Gu, J., Ulbright, T. M., MacLennan, G. T., Sweeney, C. J., Zhang, S., . . . Eble, J. N. (2002). Precise microdissection of human bladder carcinomas reveals divergent tumor subclones in the same tumor. Cancer, 94(1), 104-110.
Scopus72 Europe PMC422002 Seo, Y. R., Sweeney, C., & Smith, M. L. (2002). Selenomethionine induction of DNA repair response in human fibroblasts. Oncogene, 21(23), 3663-3669.
Scopus114 Europe PMC642001 Miller, K. D., Sweeney, C. J., & Sledge, J. (2001). Redefining the target: Chemotherapeutics as antiangiogenics. Journal of Clinical Oncology, 19(4), 1195-1206.
Scopus390 Europe PMC2152001 Sweeney, C. J., Zhu, J., Sandler, A. B., Schiller, J., Belani, C. P., Langer, C., . . . Johnson, D. H. (2001). Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: A phase III trial in patients with metastatic nonsmall cell lung carcinoma. Cancer, 92(10), 2639-2647.
Scopus243 Europe PMC1542001 Yip-Schneider, M. T., Sweeney, C. J., Jung, S. H., Crowell, P. L., & Marshall, M. S. (2001). Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. Journal of Pharmacology and Experimental Therapeutics, 298(3), 976-985.
Scopus94 Europe PMC582001 Sweeney, C. J., Miller, K. D., Sissons, S. E., Nozaki, S., Heilman, D. K., Shen, J., & Sledge, G. W. (2001). The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Research, 61(8), 3369-3372.
Scopus318 Europe PMC1922001 Sweeney, C. (2001). History of testicular cancer chemotherapy: Maximizing efficacy, minimizing toxicity. Seminars in Urologic Oncology, 19(3), 170-179.
Scopus9 Europe PMC42000 Sweeney, C. J., Hermans, B. P., Heilman, D. K., Foster, R. S., Donohue, J. P., & Einhorn, L. H. (2000). Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma-predominant testis cancer. Journal of Clinical Oncology, 18(2), 358-362.
Scopus105 Europe PMC632000 Sweeney, C. J., & Sandler, A. B. (2000). Chemotherapy in non-small cell lung cancer. Investigational New Drugs, 18(2), 157-186.
Scopus6 Europe PMC42000 Yip-Schneider, M. T., Barnard, D. S., Billings, S. D., Cheng, L., Heilman, D. K., Lin, A., . . . Sweeney, C. J. (2000). Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis, 21(2), 139-146.
Scopus276 Europe PMC1832000 Hermans, B. P., Sweeney, C. J., Foster, R. S., Einhorn, L. E., & Donohue, J. P. (2000). Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection. Journal of Urology, 163(6), 1721-1724.
Scopus87 Europe PMC561999 Yip-Schneider, M. T., Lin, A., Barnard, D., Sweeney, C. J., & Marshall, M. S. (1999). Lack of elevated MAP kinase (Erk) activity in pancreatic carcinomas despite oncogenic K-ras expression.. International journal of oncology, 15(2), 271-279.
Scopus70 Europe PMC421999 Sweeney, C. J., Williams, S. D., Finch, D. E., Bihrle, R., Foster, R. S., Collins, M., . . . Roth, B. J. (1999). A phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium. Cancer, 86(3), 514-518.
Scopus65 Europe PMC431998 Michael, H., Hull, M. T., Foster, R. S., Sweeney, C. J., & Ulbright, T. M. (1998). Nephroblastoma-like tumors in patients with testicular germ cell tumors. American Journal of Surgical Pathology, 22(9), 1107-1114.
Scopus35 Europe PMC241998 Sweeney, C. J., & Sandler, A. B. (1998). Treatment of advanced (stages III and IV) non-small-cell lung cancer.. Current problems in cancer, 22(2), 85-132.
Scopus15 Europe PMC61998 McCarthy, L. J., Porcu, P., Fausel, C. A., Sweeney, C. J., & Danielson, C. F. M. (1998). Thrombotic thrombocytopenic purpura and simvastatin. Lancet, 352(9136), 1284-1285.
Scopus43 Europe PMC241998 Sweeney, C. J., Ghassemi, M., Agger, W. A., & Persing, D. H. (1998). Coinfection with Babesia microti and Borrelia burgdorferi in a Western Wisconsin resident. Mayo Clinic Proceedings, 73(4), 338-341.
Scopus211997 Chand, V., Sweeney, C., & Agger, W. A. (1997). Mental neuropathy in patients with AIDS-associated malignant lymphoma. Clinical Infectious Diseases, 24(3), 521-522.
Scopus9 Europe PMC61997 Sweeney, C. J., & Agger, W. A. (1997). Aids-related lymphomas with neurologic manifestations. Western Journal of Medicine, 167(1), 40-44.
Scopus1 Europe PMC11995 Sweeney, C. J., & Witte, R. S. (1995). Thrombocytopenia and pancreatic carcinoma. Wisconsin Medical Journal, 94(11), 611-615.
Scopus1 -
Book Chapters
Year Citation 2006 Moore, A. M., Sweeney, C. J., Wick, M. R., & Loehrer, P. J. (2006). Thymoma and Thymic Carcinoma. In Textbook of Uncommon Cancer, Third Edition (pp. 237-256). Wiley.
-
Conference Papers
Year Citation 2023 Phillips, R., Proudfoot, J. A., Davicioni, E., Liu, Y., Spratt, D. E., Feng, F. Y., . . . Tran, P. T. (2023). Basal-luminal subtyping of localized high-risk prostate cancer and benefit of adding docetaxel to definitive radiotherapy with androgen suppression in the NRG Oncology/RTOG 0521 phase III trial. In JOURNAL OF CLINICAL ONCOLOGY Vol. 41 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. 2023 Sutera, P., Shetty, A., Hakansson, A. K., Van der Eecken, K., Song, Y., Liu, Y., . . . Ost, P. (2023). Transcriptomic heterogeneity of metastatic disease timing within metastatic castrationsensitive prostate cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 41 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. 2023 Halabi, S., Guo, S. S., Roy, A., Rydzewska, L., Godolphin, P., Hussain, M. H. A., . . . Sweeney, C. (2023). The relationship between a priori defined prognostic risk groups and and overall survival (OS) in men with metastatic hormone sensitive prostate cancer (mHSPC). In JOURNAL OF CLINICAL ONCOLOGY Vol. 41 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. 2023 Hamid, A., Chinsky, T. M., Vergara, M., Grist, E., Attard, G., Van Allen, E. M., . . . Sweeney, C. (2023). Landscape and impact of germline pathogenic variants (PVs) in metastatic hormone sensitive prostate cancer (mHSPC): Ancillary study of E3805 CHAARTED. In JOURNAL OF CLINICAL ONCOLOGY Vol. 41 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. 2023 Niazi, T., McBride, S. M., Williams, S., Davis, I. D., Stockler, M. R., Martin, A. J., . . . Sweeney, C. (2023). DASL-HiCaP: A randomized, phase 3, double-blind trial of darolutamide with androgen-deprivation therapy and definitive or salvage radiation for localized very high-risk prostate cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 41 (pp. 1 page). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. 2023 Gennusa, V., Saieva, C., Lee-Ying, R. M., Nuzzo, P. V., Spinelli, G. P., Zanardi, E., . . . Francini, E. (2023). Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS- Meet-URO 26 study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 41 (pp. 1 page). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. 2023 Ravi, P., Huang, J., Xie, W., Whelpley, B., Kelly, E., McGregor, B. A., . . . Choudhury, A. D. (2023). Outcomes with metastasis-directed therapy (MDT) and fixed-duration systemic therapy in oligometastatic hormone-sensitive prostate cancer (omHSPC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 41 (pp. 1 page). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. 2023 Weiner, A. B., Liu, Y., Hakansson, A. K., Zhao, X., Proudfoot, J. A., Zhang, J. J. H., . . . Schaeffer, E. M. (2023). Use of prostate cancer subtyping by gene expression to predict response to radiation and chemohormonal therapies.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 41 (pp. 1 page). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. 2023 Lee-Ying, R. M., Saieva, C., Nuzzo, P. V., Malgeri, A., Fotia, G., Zanardi, E., . . . Francini, E. (2023). Clinical outcomes of abiraterone acetate (AA) or enzalutamide (E) as first-line therapy (Rx) for men aged ≥75 with metastatic castration-resistant prostate cancer (mCRPC) according to previous use of docetaxel (D) for metastatic castration-sensitive prostate cancer (mCSPC) in a multicenter international registry: A SPARTACUSS - Meet-URO 26 study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 41 (pp. 1 page). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. 2023 Gordoa, T. A., Goodman, M. M., Vulsteke, C., Roubaud, G., Zhang, J., Parikh, M., . . . Sweeney, C. (2023). Phase 2 study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients (pts) with progressive metastatic castrate-resistant prostate cancer (mCRPC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 41 (pp. 1 page). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS.
WoS12023 Sutera, P., Shetty, A., Hakansson, A., Van der Eecken, K., Song, Y., Liu, Y., . . . Ost, P. (2023). Transcriptomic Heterogeneity of Metastatic Disease Timing within Metastatic Castration-Sensitive Prostate Cancer. In INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS Vol. 117 (pp. E261-E262). CA, San Diego: ELSEVIER SCIENCE INC. 2023 Halabi, S., Roy, A., Guo, S., Rydzewska, L., Godolphin, P. J., Parmar, M. K., . . . Sweeney, C. (2023). Assessing PSA. In ANNALS OF ONCOLOGY Vol. 34 (pp. S994-S995). SPAIN, Barcelona: ELSEVIER.
2023 Sutera, P., Deek, M. P., Jing, Y., Pryor, D. I., Huynh, M. A., Koontz, B. F., . . . Sweeney, C. (2023). Multi -Institutional Analysis of Metastasis Directed Therapy with or without Androgen Deprivation Therapy in Oligometastatic Castration Sensitive Prostate Cancer. In INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS Vol. 117 (pp. E442-E443). CA, San Diego: ELSEVIER SCIENCE INC.
2023 Phillips, R., Proudfoot, J., Davicioni, E., Spratt, D. E., Feng, F. Y., Simko, J., . . . Tran, P. T. (2023). Validation of a Genomic Classifier in the NRG Oncology/ RTOG 0521 Phase Ill Trial of Docetaxel with Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer. In INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS Vol. 117 (pp. S34-S35). CA, San Diego: ELSEVIER SCIENCE INC. 2023 Xie, W., Ravi, P., Buyse, M. E., Halabi, S., Kantoff, P. W., Sartor, O., . . . Sweeney, C. (2023). ICECaP-2: Validation of metastasis-free survival (MFS) as a surrogate for overall survival (OS) in localized prostate cancer (LPC) in a more contemporary era. In ANNALS OF ONCOLOGY Vol. 34 (pp. S958-S959). SPAIN, Barcelona: ELSEVIER.
2023 Morgans, A. K., Sweeney, C., Wallis, C., Halabi, S., Armstrong, A. J., Mohamed, A. F., . . . Grimm, M. -O. (2023). Health-related quality of life (HRQoL) deterioration-free survival (DetFS) by prostate-specific antigen (PSA) decline in darolutamide (DARO)-treated patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) from ARAMIS. In ANNALS OF ONCOLOGY Vol. 34 (pp. S962). SPAIN, Barcelona: ELSEVIER.
2023 Ravi, P., Xie, W., Buyse, M. E., Halabi, S., Kantoff, P. W., Sartor, O., . . . Sweeney, C. (2023). Refining risk stratification in patients undergoing radiotherapy (RT) and long-term (lt) ADT for high-risk/locally advanced prostate cancer (HR/LA-PC): An individual patient data (IPD) analysis of randomized controlled trials (RCTs) from the ICECaP consortium. In ANNALS OF ONCOLOGY Vol. 34 (pp. S954). SPAIN, Barcelona: ELSEVIER.
2022 Davis, I. D., Martin, A. J., Zielinski, R. R., Thomson, A., Tan, T. H., Sandhu, S., . . . Sweeney, C. (2022). Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 40 (pp. 1 page). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS.
WoS62022 Niazi, T., McBride, S. M., Williams, S., Davis, I. D., Stockler, M. R., Martin, A. J., . . . Sweeney, C. (2022). DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)-A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation. In JOURNAL OF CLINICAL ONCOLOGY Vol. 40 (pp. 1 page). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. 2022 Morgans, A. K., Sweeney, C., Wallis, C. J. D., Halabi, S., Armstrong, A. J., Verholen, F., . . . Grimm, M. -O. (2022). Progression patterns by types of metastatic spread, prostate-specific antigen (PSA), and clinical symptoms: Post-hoc analyses of ARAMIS.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 40 (pp. 1 page). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. 2021 Lage, D. E., Michaelson, D. M., Sweeney, C., Barrett, E. D., Olivier, K. M., Lee, R. J., . . . Nipp, R. D. (2021). Symptom burden, functional status, and clinical outcomes of hospitalized patients with advanced genitourinary cancers.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 39 (pp. 2 pages). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS.
2021 Sternberg, C. N., Bracarda, S., de Bono, J. S., Sweeney, C., Chi, K. N., Olmos, D., . . . Matsubara, N. (2021). Safety analysis of the phase III IPATential150 trial of ipatasertib (ipat) plus abiraterone (abi) in patients with metastatic castration-resistant prostate cancer (mCRPC). In ANNALS OF ONCOLOGY Vol. 32 (pp. S635-S636). ELECTR NETWORK: ELSEVIER.
2021 Sutera, P., Van der Eecken, K., Kishan, A. U., Hamid, A., Grist, E., Attard, G., . . . Deek, M. P. (2021). Emerging Prognostic Groups Across the Spectrum of Metastatic Castration-Sensitive Prostate Cancer: Disease Outcomes and Genomics. In International journal of radiation oncology, biology, physics Vol. 111 (pp. e294-e295). ELSEVIER SCIENCE INC.
2020 de Bono, J. S., Bracarda, S., Sternberg, C. N., Chi, K. N., Olmos, D., Sandhu, S., . . . Sweeney, C. (2020). IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC). In ANNALS OF ONCOLOGY Vol. 31 (pp. S1153-S1154). ELECTR NETWORK: ELSEVIER.
WoS292020 Niazi, T., Williams, S., Davis, I. D., Stockler, M. R., Martin, A., Bracken, K., . . . Sweeney, C. (2020). DASL-HiCaP: Darolutamide augments standard therapy for localised very high-risk cancer of the prostate (ANZUP1801). A randomised phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation. In ANNALS OF ONCOLOGY Vol. 31 (pp. S548-S549). ELECTR NETWORK: ELSEVIER.
2020 Smith, M. R., Agarwal, N., Todenhoefer, T., Trepiakas, R., Lee, J. -L., Lithio, A., . . . Sweeney, C. (2020). CYCLONE 2: A phase II, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 38 (pp. 2 pages). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. 2020 Sweeney, C. J., Gillessen, S., Rathkopf, D., Matsubara, N., Drake, C., Fizazi, K., . . . Powles, T. (2020). IMbassador250: A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC). In CANCER RESEARCH Vol. 80 (pp. 3 pages). Philadelphia, PA, USA: AMER ASSOC CANCER RESEARCH.
WoS362020 Ravi, P., Martin, N. E., Quoc-Dien, T., Shaw, G., Pomerantz, M., Preston, M. A., . . . Sweeney, C. (2020). Impact of MRI on outcomes in active surveillance (AS) for localized prostate cancer in a hospital registry. In JOURNAL OF CLINICAL ONCOLOGY Vol. 38 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. 2020 Niazi, T., Williams, S., Davis, I. D., Stockler, M. R., Martin, A. J., Hague, W., . . . Sweeney, C. (2020). DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostate-A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically localized prostate cancer. In JOURNAL OF CLINICAL ONCOLOGY Vol. 38 (pp. 2 pages). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
WoS22020 Shi, Z., Sweeney, C., Bracarda, S., Sternberg, C. N., Chi, K. N., Olmos, D., . . . De Bono, J. S. (2020). Biomarker analysis of the phase III IPATential150 trial of first-line ipatasertib (Ipat) plus abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC). In JOURNAL OF CLINICAL ONCOLOGY Vol. 38 (pp. 2 pages). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
WoS112020 Francini, E., Ou, F. -S., Rhoades, J., Wolfe, E. G., O'Connor, E., Ha, G., . . . Choudhury, A. D. (2020). Circulating-free DNA (cfDNA) as biomarker of taxane resistance in metastatic castration-resistant prostate cancer (mCRPC). In JOURNAL OF CLINICAL ONCOLOGY Vol. 38 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. 2020 Francini, E., Montagnani, F., Nuzzo, P. V., Gonzalez-Velez, M., Alimohamed, N. S., Cigliola, A., . . . Heng, D. Y. C. (2020). Clinical outcomes of abiraterone acetate plus prednisone (AA) plus bone resorption inhibitors (BRI) versus AA alone as first-line therapy for castration-resistant prostate cancer (CRPC) with bone metastases (BM) in an international multicenter database. In JOURNAL OF CLINICAL ONCOLOGY Vol. 38 (pp. 2 pages). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. 2020 Agarwal, A., Nassar, A., Nagy, R., Curran, C., Abou Alaiwi, S., Lanman, R. B., . . . Sonpavde, G. (2020). Circulating tumor (ct)-DNA alterations in patients with testicular germ cell tumors. In JOURNAL OF CLINICAL ONCOLOGY Vol. 38 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. 2020 Berchuck, J. E., Silver, R., Bakouny, Z., Abou Alaiwi, S., Hamid, A., Sweeney, C., . . . Taplin, M. -E. (2020). Response to olaparib or carboplatin in a real-world cohort of men with DNA damage repair (DDR) deficient metastatic castration-resistant prostate cancer (mCRPC). In JOURNAL OF CLINICAL ONCOLOGY Vol. 38 (pp. 2 pages). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
WoS22020 Grist, E., Parry, M., Mendes, L., Lall, S., Kudahetti, S. C., Vidal, S. S., . . . Attard, G. (2020). Multiregion expression profiling of prostate cancer from men randomized in the STAMPEDE trial: Stage I results of a multistage biomarker analysis. In JOURNAL OF CLINICAL ONCOLOGY Vol. 38 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. 2020 Hamid, A., Wang, X. V., Chen, Y. -H., Feng, F. Y., Benjamin, D. R., Attard, G., . . . Sweeney, C. (2020). Luminal B subtype as a predictive biomarker of docetaxel benefit for newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A correlative study of E3805 CHAARTED. In JOURNAL OF CLINICAL ONCOLOGY Vol. 38 (pp. 2 pages). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
WoS102020 Jiang, D. M., Wong, B., Morgans, A. K., Sweeney, C., Fizazi, K., Chi, K. N., . . . Sridhar, S. S. (2020). Improving quality of health-related quality of life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic prostate cancer (mPC). In JOURNAL OF CLINICAL ONCOLOGY Vol. 38 (pp. 2 pages). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. 2020 Yoshikawa, Y., Wang, X. V., Chen, Y. -H., Mazzu, Y. Z., Chakraborty, G., Jehane, L. E., . . . Sweeney, C. (2020). The impact of the expression of the transcription factor MYBL2 on outcomes of patients with localized and advanced prostate cancer. In JOURNAL OF CLINICAL ONCOLOGY Vol. 38 (pp. 2 pages). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
WoS12019 Hearn, J. W., Sweeney, C., Almassi, N., Reichard, C. A., Reddy, C. A., Hobbs, B., . . . Sharifi, N. (2019). HSD3B1 and overall survival (OS) in men with low-volume (LV) metastatic prostate cancer (PCa) treated with androgen deprivation therapy (ADT) or chemohormonal therapy in the CHAARTED Randomized trial.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37 (pp. 2 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
WoS22019 Nassar, A., Agarwal, A., Nagy, R., Curran, C., Abou Alaiwi, S., Lanman, R. B., . . . Sonpavde, G. (2019). Circulating tumor (ct)-DNA alterations in patients with testicular germ tumors.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37 (pp. 2 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
WoS12019 Sweeney, C., Percent, I. J., Babu, S., Cultrera, J., Mehlhaff, B. A., Goodman, O. B., . . . Bendell, J. C. (2019). Phase 1b/2 study of enzalutamide (ENZ) with LY3023414 (LY) or placebo (PL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37 (pp. 2 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
WoS102019 Hamid, A., Werner, L., Huang, Y., Vicier, C., Morel, K., Ellis, L., & Sweeney, C. (2019). Prognostic impact of tristetraprolin (TTP) and PTEN loss and assessment of associated immune infiltrates in localized prostate cancer (PrCa).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37 (pp. 2 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
2019 Vicier, C., Xie, W., Hamid, A., Evan, C., & Sweeney, C. (2019). Impact of new systemic therapies on outcomes of patients with non-metastatic castration resistant prostate cancer (nmCRPC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37 (pp. 2 pages). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
WoS12019 Jiang, D. M., Brundage, M. D., Sweeney, C., Fizazi, K., Bellmunt, J., Vaughn, D. J., . . . Sridhar, S. S. (2019). Health-Related Quality of Life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic prostate adenocarcinoma (mPCa) and urothelial carcinoma (mUC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37 (pp. 2 pages). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
WoS12019 Vicier, C., Werner, L., Huang, Y., Hamid, A., Evan, C., Loda, M., & Sweeney, C. (2019). Immune infiltrate with CD8 low or PDL1 high associated with metastatic prostate cancer after radical prostatectomy (RP).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37 (pp. 2 pages). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
WoS22019 Vatnick, D. R., Aktar, S., Stopfer, J. E., Kipnis, L., Culver, S. K., Koeller, D. R., . . . Pomerantz, M. (2019). Genetic counseling processes and outcomes among prostate cancer patients (ProGen).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
WoS12019 Sweeney, C., Martin, A. J., Zielinski, R. R., Thomson, A., Tan, T. H., Sandhu, S. K., . . . Davis, I. D. (2019). Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone -sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37 (pp. 2 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
WoS12018 Tripathi, A., Xie, W., Sweeney, C., Choudhury, A. D., Pomerantz, M., Wei, X. X., . . . Harshman, L. C. (2018). Impact of SLCO1B3 single nucleotide polymorphisms (SNPs) on outcomes in patients with castration resistant prostate cancer (CRPC) treated with docetaxel.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 2 pages). AMER SOC CLINICAL ONCOLOGY.
2018 Zhang, L., Gray, K. P., Shaw, G., Evan, C., Francini, E., & Sweeney, C. (2018). Bone targeted therapy and skeletal related events in the era of modern therapies for castration resistant prostate cancer with bone metastases.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 1 page). AMER SOC CLINICAL ONCOLOGY.
2018 Aldubayan, S. H., Pyle, L. T., Loud, J. T., Greene, M. H., Sweeney, C., Nathanson, K., . . . Lessel, D. (2018). Inherited defects in checkpoint kinase 2 (CHEK2) to confer increased susceptibility to testicular germ cell tumors.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 1 page). AMER SOC CLINICAL ONCOLOGY.
WoS12018 Bernard, B. D., Gray, K. P., Shaw, G., MacConaill, L. E., Evan, C., Hamid, A., . . . Sweeney, C. (2018). DNA damage and repair (DDR) gene variants and outcomes in localized and metastatic prostate cancer (mPC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
2018 Hamid, A., Gray, K. P., Huang, Y., Bowden, M., Loda, M., Pomerantz, M., & Sweeney, C. (2018). Association of low PTEN expression by fluorescence immunohistochemistry (F-IHC) and lethal disease in men with surgically-treated prostate cancer (PrCa).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
2018 Tripathi, A., Supko, J., Gray, K., Melnick, Z., Taplin, M. -E., Choudhury, A., . . . Harshman, L. (2018). Pharmacokinetic (PK) analysis of concurrent administration of enzalutamide (enza) and crizotinib (crizo) in patients with metastatic castration resistant prostate cancer (CRPC). In ANNALS OF ONCOLOGY Vol. 29 (pp. 298). Munich, GERMANY: OXFORD UNIV PRESS.
WoS12018 Morgans, A., Chen, Y. -H., Jerrard, D., Carducci, M., Dipaola, R., Wagner, L., . . . Sweeney, C. (2018). Association between patient reported quality of life (QOL) and survival: Analysis of E3805 chemohormonal androgen ablation randomized trial in prostate cancer. In ANNALS OF ONCOLOGY Vol. 29 (pp. 1 page). Munich, GERMANY: OXFORD UNIV PRESS.
2018 de Velasco, G., Lora, D., Lorente, D., Choueiri, T. K., Sweeney, C., & Castellano, D. E. (2018). Impact of statins on outcomes in patients (pts) with metastatic castration resistant prostate cancer (mCRPC): Post-hoc analysis of data from COU-AA-301 and COU-AA-302 trials.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 2 pages). San Francisco, CA: LIPPINCOTT WILLIAMS & WILKINS.
WoS32018 Williams, S., Davis, I. D., Sweeney, C., Stockler, M. R., Martin, A. J., Hague, W., . . . Nguyen, P. L. (2018). Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for high risk, clinically localized prostate cancer: ENZARAD (ANZUP 1303).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
WoS22018 Hamid, A., Gray, K. P., Shaw, G., MacConaill, L. E., Evan, C., Bernard, B. D., . . . Sweeney, C. (2018). Tumor suppressor aberrations and outcomes in localized and metastatic hormone sensitive prostate cancer (PrCa).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 1 page). San Francisco, CA: LIPPINCOTT WILLIAMS & WILKINS.
2018 Francini, E., Gray, K. P., Shaw, G., Evan, C., Hamid, A., Perry, C. E., . . . Sweeney, C. (2018). Impact of new systemic therapies on overall survival (OS) of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) in a hospital-based registry.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
WoS12018 Hamid, A., Gray, K. P., Shaw, G., MacConaill, L. E., Evan, C., Bernard, B. D., . . . Sweeney, C. (2018). Clinical outcomes with cumulative tumor suppressor gene (TSG) alterations in castration sensitive (CSPC) and resistant (CRPC) prostate cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 2 pages). AMER SOC CLINICAL ONCOLOGY.
2018 Wei, X. X., Hamid, A., He, M., Harshman, L. C., Choueiri, T. K., Sonpavde, G., . . . Choudhury, A. D. (2018). Delayed PSA responses in metastatic castration resistant prostate cancer (mCRPC) patients (pts) treated with sipuleucel-T.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 1 page). AMER SOC CLINICAL ONCOLOGY.
2017 Yang, D. D., Mahal, B. A. V., Sweeney, C., Quoc-Dien, T., Feng, F. Y. -C., & Nguyen, P. L. (2017). Identification of low prostate-specific antigen, high Gleason prostate cancer as a unique hormone-resistant entity with poor survival: A contemporary analysis of 640,000 patients.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 5 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
WoS12017 Powles, T., Fizazi, K., Gillessen, S., Drake, C. G., Rathkopf, D. E., Narayanan, S., . . . Sweeney, C. (2017). A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 5 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
WoS22017 Sweeney, C., Gerke, T., Beltran, H., Sboner, A., Karnes, R. J., Klein, E. A., . . . Trock, B. (2017). Association of loss of tumor suppressor ZFP36 with lethal prostate cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 5 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
2017 Hainsworth, J. D., Bose, R., Sweeney, C., Meric-Bernstam, F., Hurwitz, H., Swanton, C., . . . Spigel, D. R. (2017). Targeted therapy for non-small cell lung cancer (NSCLC) with HER2, BRAF, or hedgehog alterations: Interim data from MyPathway.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 5 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
WoS62017 Francini, E., Gray, K. P., Evan, C., Kaymakcalan, M. D., Shaw, G. K., Kantoff, P. W., . . . Sweeney, C. (2017). Outcomes of prechemotherapy (pCHT) abiraterone (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after androgen deprivation therapy (ADT) plus docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a hospital-based registry.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 5 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
WoS12017 Howard, S., Rosenthal, M., Qin, L., Matalon, S., Bernard, B., Beard, C., & Sweeney, C. (2017). Quantifying Decreased Radiation Exposure From Modern CT Scan Technology and Surveillance Programs of Germ Cell Tumors. In American Journal of Clinical Oncology: Cancer Clinical Trials Vol. 34 (pp. 1-4). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
Scopus4 WoS4 Europe PMC32016 Ko, J. J., Bernard, B. D., Ben, T., Li, H., Asif, T., Stukalin, I., . . . Heng, D. Y. C. (2016). Conditional survival of patients with metastatic testicular germ-cell tumors (MT-GCT) treated with first-line curative therapy.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 1 page). San Francisco, CA: LIPPINCOTT WILLIAMS & WILKINS.
2016 Hurwitz, H., Hainsworth, J. D., Swanton, C., Perez, E. A., Sweeney, C., Burris, H. A., . . . Bose, R. (2016). Targeted therapy for gastrointestinaI (GI) tumors based on molecular profiles: Early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tumors.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
WoS142016 Patrick-Miller, L. J., Chen, Y. -H., Carducci, M. A., Cella, D., DiPaola, R. S., Gartrell, B. A., . . . Sweeney, C. (2016). Quality of life (QOL) analysis from E3805, chemohormonal androgen ablation randomized trial (CHAARTED) in prostate cancer (PrCa). In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
WoS42016 Bernard, B. D., Albiges, L., Signoretti, S., Novak, J., Hirsch, M. S., Massard, C., . . . Adam, J. (2016). Programmed death-ligand 1 (PD-L1) expression in cured and not cured testicular and other germ cell tumors (GCT).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
2016 Harshman, L. C., Werner, L., Nakabayashi, M., Tripathi, A., Mckay, R. R., Wang, X., . . . Kantoff, P. W. (2016). The impact of statin use on abiraterone acetate (AA) treatment duration in patients with castration-resistant prostate cancer (CRPC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
2016 Muralidhar, V., Mahal, B. A. V., Reznor, G., Choueiri, T. K., Sweeney, C., Martin, N. E., . . . Nguyen, P. L. (2016). Variation in national use of long-term ADT by disease aggressiveness among men with unfavorable-risk prostate cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
2016 Pomerantz, M., Wang, X. V., Kantoff, P. W., Xie, W., Kohli, M., Lee, G. -S. M., . . . Sweeney, C. (2016). Genome-wide association study (GWAS) of response to androgen deprivation therapy (ADT) and survival in metastatic prostate cancer (PCa). In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 2 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
WoS12016 Harshman, L. C., Gray, K. P., Polacek, L., Taplin, M. -E., Choudhury, A. D., Pomerantz, M. M., . . . Sweeney, C. (2016). An investigator-initiated phase I study of crizotinib in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) before or after progression on docetaxel.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 2 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
WoS12016 Davis, I. D., Stockler, M. R., Martin, A. J., Hague, W., Coskinas, X., Yip, S., . . . Sweeney, C. (2016). Randomised phase 3 trial of enzalutamide in first-line androgen deprivation therapy for metastatic prostate cancer: The ANZUP ENZAMET Trial (ANZUP 1304).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 3 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
2016 Williams, S. G., Davis, I. D., Sweeney, C., Stockler, M. R., Martin, A. J., Hague, W., . . . Nguyen, P. L. (2016). Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised high-risk or node-positive prostate cancer: ENZARAD (ANZUP 1303).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 3 pages). IL, Chicago: AMER SOC CLINICAL ONCOLOGY.
2016 Friedland, D., Barry, A., Ellis, P. G., Sweeney, C., McCutcheon, S., Lokay, K., . . . Krebs, M. (2016). Evaluating the impact of Via Pathways (VP) on the adoption of changing treatment paradigms in metastatic hormone-sensitive prostate cancer (mHSPC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 2 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
2016 Morris, M. J., Loriot, Y., Sweeney, C., Fizazi, K., Ryan, C. J., Shevrin, D. H., . . . Higano, C. S. (2016). Updated results: A phase InIa randomized trial of radium-223+docetaxel versus docetaxel in patients with castration-resistant prostate cancer and bone metastases.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 3 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
WoS92016 Sweeney, C., Xie, W., Regan, M. M., Nakabayashi, M., Buyse, M. E., Clarke, N. W., . . . Williams, S. G. (2016). Disease-free survival (DFS) as a surrogate for overall survival (OS) in localized prostate cancer (CaP).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 2 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
WoS32016 Patrick-Miller, L. J., Chen, Y. -H., Carducci, M. A., Cella, D., DiPaola, R. S., Gartrell, B. A., . . . Sweeney, C. (2016). Quality of life (QOL) analysis from CHAARTED: Chemohormonal androgen ablation randomized trial in prostate cancer (E3805).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 2 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
WoS22016 Howard, S. A. H., Rosenthal, M., Qin, L., Bernard, B. D., Beard, C., & Sweeney, C. (2016). Quantifying decreased radiation exposure from modern CT scan surveillance programs of germ cell tumors.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
2016 Wong, S. E., North, S. A., Sweeney, C., Stockler, M. R., & Sridhar, S. S. (2016). Screen failure rates in contemporary phase II/III therapeutic trials in genitourinary malignancies. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
2015 Hsieh, C. -L., Botta, G., Gao, S., Li, T., Van Allen, E. M., Treacy, D. J., . . . Kantoff, P. W. (2015). PLZF, a tumor suppressor genetically lost in metastatic castration resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy. In CANCER RESEARCH Vol. 75 (pp. 2 pages). San Francisco, CA: AMER ASSOC CANCER RESEARCH.
2015 Vale, C., Rydzewska, L. H., Tierney, J. F., Albiges, L., Clarke, N. W., Fisher, D. J., . . . Burdett, S. (2015). What is the current evidence for adding docetaxel or bisphosphonates to androgen deprivation therapy (ADT) in men with hormone sensitive prostate cancer? A systematic review and meta-analyses. In EUROPEAN JOURNAL OF CANCER Vol. 51 (pp. S719-S720). Vienna, AUSTRIA: ELSEVIER SCI LTD.
WoS22015 Dinh, K. T., Mahal, B. A. V., Ziehr, D. R., Muralidhar, V., Chen, Y. -W., Viswanathan, V. B., . . . Paul, L. N. (2015). Incidence and predictors of prostate cancer death in men with other prior malignancies: An analysis from SEER Database. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33 (pp. 1 page). Orlando, FL: AMER SOC CLINICAL ONCOLOGY.
2015 Harshman, L. C., Nakabayashi, M., Xie, W., Wang, X., Valenca, L., Werner, L., . . . Kantoff, P. W. (2015). Statin use at the time of initiation of androgen deprivation therapy (ADT) and time to progression (TTP) in patients with hormone-sensitive prostate cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33 (pp. 1 page). Orlando, FL: AMER SOC CLINICAL ONCOLOGY.
2015 Bernard, B. D., Markt, S. C., Albiges, L., Miller, R., Pettersson, A., Beard, C., & Sweeney, C. (2015). Sunlight and testicular germ cell tumor rates in the USA. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
2015 Kamran, S. C., Markt, S. C., Miller, R., O'Donnell, E., Bernard, B. D., Curreri, S. A., . . . Beard, C. (2015). A review of clinical stage 1 testicular cancer mortality in a high-volume center. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33 (pp. 1 page). Orlando, FL: AMER SOC CLINICAL ONCOLOGY.
WoS12015 Harshman, L. C., Wang, X., Nakabayashi, M., Xie, W., Valenca, L. B., Werner, L., . . . Kantoff, P. W. (2015). Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive prostate cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
2014 Beard, C. J., Jeldres, C., Odem-Davis, K., Hoffman, K. E., Martin, N. E., Nguyen, P. L., . . . Nichols, C. R. (2014). Variation in Patterns of Care in the United States for Clinical Stage I Seminoma: Results From the National Cancer Data Base (1998-2011). In INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS Vol. 90 (pp. S469). San Francisco, CA: ELSEVIER SCIENCE INC.
2013 Sweeney, C. J., Zukotynski, K., Wang, X., Wick, A., Fredericks, A., Lam, B., & Kantoff, P. (2013). Cabozantinib (cabo) plus abiraterone (abi) combination therapy in castration resistant prostate cancer (CRPC): preclinical evaluation and interim results of an investigator-sponsored phase 1 clinical study.. In CANCER RESEARCH Vol. 73 (pp. 1 page). Washington, DC: AMER ASSOC CANCER RESEARCH.
2012 Morris, M. J., Hammers, H. J., Sweeney, C., Bloma, M., Aksnes, A. -K., O'Bryan-Tear, C. G., & Carrasquillo, J. A. (2012). A phase I/IIa study of the safety and efficacy of radium-223 chloride (Ra-223) with docetaxel (D) for castration-resistant prostate cancer (CRPC) patients with bone metastases.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 30 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
WoS12012 Hutson, T. E., Dang, L. H., Lauer, R. C., Starodub, A., Hauke, R. J., Galsky, M. D., . . . Sarantopoulos, J. (2012). Phase I results of a phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC) patients previously treated with VEGFR tyrosine kinase inhibitors. In JOURNAL OF CLINICAL ONCOLOGY Vol. 30 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. 2012 de Bono, J. S., Smith, M. R., Rathkopf, D., Corn, P. G., Mukherji, D., Harzstark, A. L., . . . Sweeney, C. (2012). CABOZANTINIB (XL184) AT 40 MG IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC): RESULTS OF A PHASE 2 NON-RANDOMIZED EXPANSION COHORT (NRE). In ANNALS OF ONCOLOGY Vol. 23 (pp. 296). Vienna, AUSTRIA: OXFORD UNIV PRESS. 2012 Rudman, S. M., Gray, K. P., Kasperzyk, J., Giovannucci, E., Pitt, M., Loda, M. F., . . . Sweeney, C. (2012). Association of metabolic syndrome with poorer prostate cancer and overall survival in men receiving androgen deprivation therapy (ADT) for biochemical relapse.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 30 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. 2012 Smith, M. R., Sweeney, C., Rathkopf, D. E., Scher, H. I., Logothetis, C., George, D. J., . . . Corn, P. G. (2012). Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II nonrandomized expansion cohort (NRE). In JOURNAL OF CLINICAL ONCOLOGY Vol. 30 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
WoS52010 Arvold, N. D., Catalano, P. J., Sweeney, C. J., Hoffman, K. E., Nguyen, P. L., Balboni, T. A., . . . Beard, C. J. (2010). Patterns of Care for Stage I Seminoma: A Survey of American Radiation Oncologists. In INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS Vol. 78 (pp. S193). San Diego, CA: ELSEVIER SCIENCE INC.
2010 Jain, R. K., Thorat, M. A., Mehta, R., Polar, Y., Morimiya, A., Sweeney, C., . . . Badve, S. (2010). Gene Expression Profiles of Classical and Spermatocytic Seminoma. In MODERN PATHOLOGY Vol. 23 (pp. 198A). Washington, DC: NATURE PUBLISHING GROUP. 2010 Jain, R. K., Thorat, M. A., Mehta, R., Polar, Y., Morimiya, A., Sweeney, C., . . . Badve, S. (2010). Gene Expression Profiles of Classical and Spermatocytic Seminoma. In LABORATORY INVESTIGATION Vol. 90 (pp. 198A). Washington, DC: NATURE PUBLISHING GROUP. 2010 Estabrook, N. C., Chin-Sinex, H., Watson, C. N., Shapiro, R. H., Dhaemers, R. M., Gilley, D., . . . Mendonca, M. S. (2010). DMAPT Induced X-ray Sensitization of Lung Cancer Cells Involves Inhibition of NF-κB Dependent Split Dose and DNA Double Strand Break Repair. In INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS Vol. 78 (pp. S647). San Diego, CA: ELSEVIER SCIENCE INC.
2009 Clarke, S. J., Smith, J. T., Gebbie, C., Sweeney, C., & Olszewski, N. (2009). A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer. In JOURNAL OF CLINICAL ONCOLOGY Vol. 27 (pp. 2 pages). Orlando, FL: AMER SOC CLINICAL ONCOLOGY.
WoS152009 Hahn, N. M., Stadler, W. M., Zon, R. T., Waterhouse, D. M., Picus, J., Nattam, S. R., . . . Sweeney, C. J. (2009). A multicenter phase II study of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC): Hoosier Oncology Group GU-0475. In JOURNAL OF CLINICAL ONCOLOGY Vol. 27 (pp. 1 page). Orlando, FL: AMER SOC CLINICAL ONCOLOGY.
WoS62008 Chiorean, E., Sweeney, C., Youssoufian, H., Fox, F., Katz, T., Rowinsky, E., & Amato, R. (2008). Phase I study of IMC-3G3, an IgG1 monoclonal antibody targeting platelet-derived growth factor alpha (PDGFRa) in patients with advanced solid malignancies. In EJC SUPPLEMENTS Vol. 6 (pp. 162). Geneva, SWITZERLAND: PERGAMON-ELSEVIER SCIENCE LTD.
2003 Sweeney, C. J. (2003). Why cyclooxygenase-2 inhibition plus chemotherapy?. In American Journal of Clinical Oncology: Cancer Clinical Trials Vol. 26 (pp. S122-S125). United States.
Scopus14 Europe PMC7 -
Conference Items
Year Citation 2023 Ravi, P., Kwak, L., Armstrong, J., Beckendorf, V., Chin, J., D'Amico, A. V., . . . Sweeney, C. (2023). Prognostic impact of PSA nadir (n) >= 0.1 ng/mL within 6 months (m) after completion of radiotherapy (RT) for localized prostate cancer (PCa): An individual patient-data (IPD) analysis of randomized trials from the ICECAP collaborative.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. 2023 Lledo, D. S., Chu, X., Jarrard, D. F., Carducci, M. A., DiPaola, R. S., Wagner, L. I., . . . Morgans, A. K. (2023). Patient reported quality of life (QOL) and survival outcomes: Analysis of ECOG-ACRIN E3805 chemohormonal androgen ablation randomized trial (CHAARTED) in prostate cancer (PCa). Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. 2023 Halabi, S., Roy, A., Guo, S. S., Rydzewska, L., Godolphin, P., Hussain, M. H. A., . . . Sweeney, C. (2023). Assessing PSA levels as prognostic of overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC). Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.
WoS12023 Cilento, M. A., Mah, C. Y., Martelotto, L., Sweeney, C. J., & Butler, L. M. (2023). Multiomic analysis workflow for biomarker discovery in human prostate cancer. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY. 2022 Shi, Z., Nowicka, M., de Bono, J., Chi, K. N., Sweeney, C., Sternberg, C. N., . . . Sandhu, S. K. (2022). Molecular subtyping in prostate cancer associate with outcomes to abiraterone and ipatasertib treatment from the phase III IPATential150 trial. Poster session presented at the meeting of CANCER RESEARCH. New Orleans, LA: AMER ASSOC CANCER RESEARCH. 2022 Shi, Z., Nowicka, M., de Bono, J., Chi, K. N., Sweeney, C., Sternberg, C. N., . . . Sandhu, S. K. (2022). Molecular subtyping in prostate cancer associate with outcomes to abiraterone and ipatasertib treatment from the phase III IPATential150 trial.. Poster session presented at the meeting of CANCER RESEARCH. New Orleans, LA: AMER ASSOC CANCER RESEARCH. 2022 Sweeney, C., Chi, K. N., Bracarda, S., Sternberg, C. N., Olmos, D., Sandhu, S., . . . De Bono, J. S. (2022). Activation of the AKT pathway and outcomes in patients (pts) treated with or without ipatasertib (ipat) in metastatic castration-resistant prostate cancer (mCRPC): Next-generation sequencing (NGS) data from the phase III IPATential150 trial.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS.
WoS12022 George, S., Gosain, R., Yendamuri, K., Boher, J. M., Mescam, G. G., Sweeney, C. J., & Hutson, A. (2022). Assessment of whether time to docetaxel impacts outcome when given in metastatic hormone-sensitive prostate cancer (MHSPC) setting. Poster session presented at the meeting of ANNALS OF ONCOLOGY. ELECTR NETWORK: ELSEVIER.
WoS12022 Halabi, S., Roy, A., Rydzewska, L., Godolphin, P., Parmar, M. K., Hussain, M., . . . Sweeney, C. J. (2022). Intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC). Poster session presented at the meeting of ANNALS OF ONCOLOGY. ELECTR NETWORK: ELSEVIER. 2022 Mckay, R. R., Agarwal, N., Matsubara, N., Rodriguez, J. M. P., Smith, M. R., Todenhofer, T., . . . Sweeney, C. J. (2022). CYCLONE 3: A phase III, randomized, double-blind, placebocontrolled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer (mHSPC). Poster session presented at the meeting of ANNALS OF ONCOLOGY. ELECTR NETWORK: ELSEVIER. 2022 Parry, M., Grist, E., Brawley, C., Proudfoot, J. A., Mendes, L., Lall, S., . . . Attard, G. (2022). Clinical qualification of transcriptome signatures for advanced prostate cancer (APC) starting androgen deprivation therapy (ADT) with or without abiraterone acetate and prednisolone (AAP): An ancillary study of the STAMPEDE AAP trial. Poster session presented at the meeting of ANNALS OF ONCOLOGY. ELECTR NETWORK: ELSEVIER.
WoS12022 Sweeney, C. J., Morel, K., Hamid, A., & Ellis, L. (2022). Combined loss of tristetraprolin (TTP) and PTEN leads to aggressive prostate cancer and hypersensitivity to nuclear factor kappa B (NFkB) inhibition.. Poster session presented at the meeting of CANCER RESEARCH. LA, New Orleans: AMER ASSOC CANCER RESEARCH. 2022 Sweeney, C. J., Morel, K., Hamid, A., & Ellis, L. (2022). Combined loss of tristetraprolin (TTP) and PTEN leads to aggressive prostate cancer and hypersensitivity to nuclear factor kappa B (NFkB) inhibition. Poster session presented at the meeting of CANCER RESEARCH. LA, New Orleans: AMER ASSOC CANCER RESEARCH. 2022 Mostaghel, E. A., Wang, X. V., Marck, B., Matsumoto, A. M., & Sweeney, C. (2022). Association of serum steroid levels with survival in men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with ADT with and without docetaxel on ECOG-ACRIN E3805.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS.
2022 McGregor, B. A., Wang, X. V., Hamnvik, O. -P. R., Cheung, Y. M., Wei, X. X., Ravi, P., . . . Sweeney, C. (2022). Changes in bone turnover markers (BTM) and association with outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) plus /- docetaxel (D) in CHAARTED (ECOG-ACRIN E3805).. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS.
2022 Smith, M. R., Agarwal, N., Todenhofer, T., Piulats, J. M., Lee, J. -L., Trepiakas, R., . . . Sweeney, C. (2022). CYCLONE 2: A phase 2/3, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS.
2022 McBride, S. M., Niazi, T., Williams, S., Davis, I. D., Stockler, M. R., Martin, A. J., . . . Sweeney, C. (2022). DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801). a randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS.
2022 Tripathi, A., Chen, Y. -H., Jarrard, D. F., Hahn, N. M., Garcia, J. A., Dreicer, R., . . . Sweeney, C. (2022). Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): An analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. 2022 Halabi, S., Roy, A., Rydzewska, L., Godolphin, P., Parmar, M. K. B., Hussain, M. H. A., . . . Sweeney, C. (2022). Assessing intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC).. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS.
WoS22021 Halabi, S., Roy, A., Yang, Q., Xie, W., Kelly, W. K., & Sweeney, C. (2021). Radiographic progression-free survival as a surrogate endpoint of overall survival in men with metastatic castrate-resistant prostate cancer.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS.
WoS32021 Mendes, L., Brawley, C. D., Grist, E., Ali, A., Vidal, S. S., Parry, M., . . . Attard, G. (2021). Proliferation index and survival in men with prostate cancer starting long-term androgen deprivation therapy in the STAMPEDE clinical trial.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS.
2021 Niazi, T., Williams, S., Davis, I. D., Stockler, M. R., Martin, A. J., Bracken, K., . . . Sweeney, C. (2021). DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)-A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS.
2021 Choudhury, A. D., Kwak, L., Cheung, A., Tripathi, A., Pace, A. F., Van Allen, E. M., . . . Bhatt, R. S. (2021). Randomized phase II study evaluating the addition of pembrolizumab to radium-223 in metastatic castration-resistant prostate cancer. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS.
WoS32021 De Bono, J. S., Sweeney, C., Bracarda, S., Sternberg, C. N., Chi, K. N., Olmos, D., . . . Shi, Z. (2021). PI3K/AKT pathway biomarkers analysis from the phase III IPATential150 trial of ipatasertib plus abiraterone in metastatic castration-resistant prostate cancer.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS.
WoS132021 Lage, D. E., Michaelson, D. M., Lee, R. J., Greer, J. A., Temel, J. S., & Sweeney, C. (2021). Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Online: LIPPINCOTT WILLIAMS & WILKINS.
2021 Brennan, V., Spektor, A., Sweeney, C., Choudhury, A. D., Rathkopf, D. E., Pomerantz, M., . . . King, M. T. (2021). Evaluating the role of stereotactic body radiation therapy with respect to androgen receptor signaling inhibitors for metastatic prostate cancer.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS.
2020 Morel, K. L., Sweeney, C. J., & Ellis, L. (2020). Targeting EZH2 and PI3K/mTOR for a novel combination therapeutic strategy in aggressive variant prostate cancer.. Poster session presented at the meeting of MOLECULAR CANCER RESEARCH. Boston, MA: AMER ASSOC CANCER RESEARCH. 2020 Sengupta, S., Niazi, T., Williams, S., Davis, I. D., Stockler, M., Martin, A. J., . . . Sweeney, C. J. (2020). DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY. 2020 Harshman, L. C., Wang, X. V., Yamamoto, H. S., Hamid, A., Drake, C. G., Carducci, M. A., . . . Sweeney, C. (2020). Impact of baseline serum IL-8 on metastatic hormone-sensitive (mHSPC) prostate cancer outcomes in the phase III CHAARTED trial (E3805). Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
WoS12019 Francini, E., Montagnani, F., Vitale, N. P., Alimohamed, N. S., Candilejo, I. M., Rosellini, P., . . . Heng, D. Y. C. (2019). Efficacy of bone resorption inhibitors (BRI) plus abiraterone acetate plus prednisone (AA) vs. AA alone as first-line therapy for men with castration-resistant prostate cancer (CRPC) and bone metastases (BM) in an international multicenter hospital-based registry.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.
2019 Hamid, A., Beltran, H., Choudhury, A. D., & Sweeney, C. (2019). Genomic predictors of benefit of docetaxel (D) and next-generation hormonal therapy (NHT) in metastatic castration resistant prostate cancer (mCRPC).. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
WoS22019 Stockler, M. R., Martin, A. J., Dhillon, H., Davis, I. D., Chi, K. N., Chowdhury, S., . . . Sweeney, C. J. (2019). Health-related quality of life (HRQL) in a randomized phase III trial of enzalutamide with standard first-line therapy for metastatic, hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led, international, co-operative group trial. Poster session presented at the meeting of ANNALS OF ONCOLOGY. Barcelona, SPAIN: OXFORD UNIV PRESS.
WoS32019 Sheahan, A., Morel, K., Burkhart, D., Baca, S., Labbe, D., Roehle, K., . . . Ellis, L. (2019). Targeting EZH2 increases therapeutic efficacy of PD-1 blockade in models of prostate cancer. Poster session presented at the meeting of MOLECULAR CANCER THERAPEUTICS. AMER ASSOC CANCER RESEARCH.
2019 Morel, K. L., Hamid, A. A., Ellis, L., & Sweeney, C. J. (2019). Dimethylaminoparthenolide-mediated inhibition of NF-κB decreases resistance to ADT by targeting AR variants in lethal prostate cancer. Poster session presented at the meeting of MOLECULAR CANCER THERAPEUTICS. AMER ASSOC CANCER RESEARCH.
2018 Allott, E. H., Ebot, E. M., Gonzalez-Feliciano, A. G., Markt, S. C., Wilson, K. M., Ahearn, T. U., . . . Mucci, L. A. (2018). Molecular tumor profiling to identify mechanisms linking statin use with lower risk of lethal prostate cancer: Results from the Health Professionals Follow-up Study.. Poster session presented at the meeting of CANCER RESEARCH. Orlando, FL: AMER ASSOC CANCER RESEARCH.
2017 Mahal, B. A., Yang, D. D., Sweeney, C., Trinh, Q. D., Feng, F. Y., & Nguyen, P. L. (2017). Identification of Low Prostate-Specific Antigen, High Gleason Prostate Cancer as a Unique Hormone-Resistant Entity With Poor Survival: A Contemporary Analysis of Over 600,000 Patients. Poster session presented at the meeting of INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. San Diego, CA: ELSEVIER SCIENCE INC.
WoS32017 Francini, E., Yip, S., Ahmed, N. S., Li, H., Ardolino, L., Evan, C. P., . . . Sweeney, C. J. (2017). Outcomes of prechemotherapy (pCRx) abiraterone acetate (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after ADT plus Docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a multi-institution hospital-based registry. Poster session presented at the meeting of ANNALS OF ONCOLOGY. Madrid, SPAIN: OXFORD UNIV PRESS. 2017 Vale, C. L., Fisher, D. J., Carpenter, J., White, I. R., Burdett, S., Clarke, N. W., . . . Tierney, J. F. (2017). What are the optimal systemic treatments for men with metastatic, hormone-sensitive prostate cancer? A STOPCaP systematic review and network meta-analysis. Poster session presented at the meeting of Abstracts of the 42nd European Society for Medical Oncology Congress (ESMO 2017), as published in Annals of Oncology. Madrid, SPAIN: Elsevier.
WoS32017 Williams, S., Davis, I. D., Sweeney, C., Stockier, M. R., Martin, A. J., Hague, W., . . . Nguyen, P. L. (2017). Randomised phase III trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised, high risk, or node-positive prostate cancer: ENZARAD (ANZUP 1303).. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
WoS12017 Mckay, R. R., Werner, L., Jones, A., Choudhury, A. D., Pomerantz, M., Sweeney, C., . . . Taplin, M. -E. (2017). A phase II trial of abiraterone acetate (AA) without prednisone in castration resistant prostate cancer (CRPC).. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
2017 Wong, S., Sweeney, C., & Sridhar, S. S. (2017). Eligibility criteria requirements and adherence in advanced prostate cancer trials. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
2017 de Bono, J., Bracarda, S., Chi, K., Massard, C., Olmos Hidalgo, D., Sandhu, S., . . . Sweeney, C. J. (2017). Randomized phase III trial of ipatasertib vs. placebo, plus abiraterone and prednisone/prednisolone, in men with asymptomatic or mildly symptomatic previously untreated metastatic castrate-resistant prostate cancer (mCRPC). Poster session presented at the meeting of ANNALS OF ONCOLOGY. Madrid, SPAIN: OXFORD UNIV PRESS.
WoS12017 Hurwitz, H., Raghav, K. P. S., Burris, H. A., Kurzrock, R., Sweeney, C., Meric-Bernstam, F., . . . Hainsworth, J. D. (2017). Pertuzumab plus trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
WoS152017 Kurzrock, R., Meric-Bernstam, F., Hurwitz, H., Hainsworth, J. D., Spigel, D. R., Bose, R., . . . Lam, E. T. (2017). Targeted therapy for advanced salivary cancer with HER2 or hedgehog alterations: Interim data from MyPathway.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
WoS72017 Sweeney, C. J., Geybels, M., Coseo-Markt, S., Wang, V., Penney, K., Gerke, T., . . . Mucci, L. (2017). A polymorphism in the promoter of the FRAS1 gene is associated with metastatic prostate cancer. Poster session presented at the meeting of ANNALS OF ONCOLOGY. Madrid, SPAIN: ELSEVIER.
WoS12016 Muralidhar, V., Regan, M. M., Werner, L., Nakabayashi, M., Evan, C., Bellmunt, J., . . . Nguyen, P. L. (2016). Duration of androgen deprivation therapy for high-risk prostate cancer: Application of randomized trial data in a tertiary referral cancer center. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
WoS22016 Sweeney, C., Chen, Y. -H., Liu, G., Carducci, M., Jarrard, D., Eisenberger, M., . . . Dipaola, R. (2016). Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naive metastatic prostate cancer (PrCa): E3805 CHAARTED trial. Poster session presented at the meeting of ANNALS OF ONCOLOGY. Copenhagen, DENMARK: OXFORD UNIV PRESS.
WoS102016 Xie, W., Sweeney, C., Regan, M., Nakabayashi, M., Buyse, M., Clarke, N., . . . Williams, S. (2016). Metastasis free survival (MFS) is a surrogate for overall survival (OS) in localized prostate cancer (CaP). Poster session presented at the meeting of Annals of Oncology. Copenhagen, Denmark: Elsevier.
Scopus4 WoS22015 Giannatempo, P., Pond, G. R., Sonpavde, G., Albany, C., Loriot, Y., Sweeney, C., . . . Necchi, A. (2015). Treatment and clinical outcomes of patients with teratoma with somatic-type malignant transformation (TMT): An international collaboration.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Orlando, FL: AMER SOC CLINICAL ONCOLOGY. 2015 Davis, I., Stockler, M., Martin, A., Hague, W., Coskinas, X., Yip, S., . . . Sweeney, C. (2015). Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: the ANZUP ENZAMET trial (ANZUP 1304). Poster session presented at the meeting of Asia-Pacific Journal of Clinical Oncology. WILEY-BLACKWELL. 2015 Williams, S., Davis, I., Sweeney, C., Stockler, M., Martin, A., Hague, W., . . . Nguyen, P. (2015). Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer: ENZARAD (ANZUP1303). Poster session presented at the meeting of Asia-Pacific Journal of Clinical Oncology. WILEY-BLACKWELL.
WoS12015 Mahal, B. A., Muralidhar, V., Dinh, K. T., Chen, Y. W., Nezolosky, M. D., Choueiri, T. K., . . . Nguyen, P. L. (2015). Gleason 5+3=8 Prostate Cancer: Much More like Gleason 9?. Poster session presented at the meeting of INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. San Antonio, TX: ELSEVIER SCIENCE INC.
2015 Muralidhar, V., Dinh, K. T., Mahal, B. A., Ziehr, D. R., Chen, Y. W., Viswanathan, V. B., . . . Nguyen, P. L. (2015). Differential Postprostatectomy Cancer-Specific Mortality of Occult T3 Versus Clinical T3 Prostate Cancer: Implications for Radiation Managed Patients Upstaged on Prostate MRI. Poster session presented at the meeting of INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. San Antonio, TX: ELSEVIER SCIENCE INC. 2015 Muralidhar, V., Ziehr, D. R., Mahal, B. A., Chen, Y. W., Nezolosky, M. D., Viswanathan, V. B., . . . Nguyen, P. L. (2015). Older Age and Increasing Gleason Score: Implications for Prostate Cancer Screening. Poster session presented at the meeting of INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. San Antonio, TX: ELSEVIER SCIENCE INC.
WoS12015 Sweeney, C., Sartor, A. O., Vogelzang, N. J., Shore, N. D., Cislo, P., Bangerter, K., & Morris, M. J. (2015). Effect of radium-223 dichloride (Ra-223) on pain from US EAP.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
WoS12015 Sweeney, C., Gray, K. P., Harshman, L. C., Taplin, M. -E., Pace, A. F., Dumas, K., . . . Kantoff, P. W. (2015). Phase 1 study with expansion cohorts of cabozantinib (C) plus abiraterone (A) in metastatic castration resistant prostate cancer (mCRPC): Investigator-sponsored study.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
WoS412015 Miller, R., Markt, S. C., O'Donnell, E., Bernard, B. D., Albiges, L., Lago-Hernandez, C., . . . Sweeney, C. (2015). Association of age 40 and older with adverse outcome in metastatic testicular cancer (TC). Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Orlando, FL: AMER SOC CLINICAL ONCOLOGY.
2015 Coulson, H., Loda, M., O'Donnell, E., Sweeney, C., & Hirsch, M. (2015). Targeted Next Generation Sequencing of Testicular Germ Cell Tumors. Poster session presented at the meeting of LABORATORY INVESTIGATION. Boston, MA: NATURE PUBLISHING GROUP. 2015 Burris, H. A., Hurwitz, H., Perez, E. A., Spigel, D., Swanton, C., Hainsworth, J. D., . . . Sweeney, C. (2015). MyPathway: An open-label phase IIa study of trastuzumab/pertuzumab, erlotinib, vemurafenib, and vismodegib in patients who have advanced solid tumors with mutations or gene expression abnormalities targeted by these agents.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
WoS12015 Sweeney, C. (2015). PRECISION MEDICINE IN PROSTATE CANCER: HOW CLOSE ARE WE?. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. Sydney, AUSTRALIA: WILEY. 2015 Sweeney, C. (2015). NEW INSIGHTS IN GCT. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. Sydney, AUSTRALIA: WILEY. 2015 Sweeney, C. (2015). IMMEDIATE DOCETAXEL IN METASTATIC PROSTATE CANCER. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. Sydney, AUSTRALIA: WILEY. 2015 Sartor, O., Coleman, R. E., Morris, M. J., Nilsson, S., Shore, N., Sweeney, C., . . . Parker, C. (2015). Baseline characteristics, number of radium-223 (Ra-223) injections, and overall survival (OS) in US Expanded Access Program (EAP) and ALSYMPCA. Poster session presented at the meeting of EUROPEAN JOURNAL OF CANCER. Vienna, AUSTRIA: ELSEVIER SCI LTD.
WoS152015 Sartor, A. O., Fernandez, D. C., Morris, M. J., Iagaru, A., Brown, A., Almeida, F., . . . Vogelzang, N. J. (2015). Ra-223 experience in pretreated patients: EAP setting.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
WoS32015 Markt, S. C., Miller, R., O'Donnell, E., Albiges, L., Bernard, B. D., Lago-Hernandez, C., . . . Sweeney, C. (2015). BMI at diagnosis and adverse outcomes among men with malignant testicular germ cell tumors. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Orlando, FL: AMER SOC CLINICAL ONCOLOGY.
2015 Gerke, T., Tyekucheva, S., Penney, K., Sweeney, C., Lis, R., Sesso, H. D., . . . Mucci, L. A. (2015). Discovery and validation of a 30-gene expression signature to identify prostate cancer patients who are candidates for active surveillance. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Orlando, FL: AMER SOC CLINICAL ONCOLOGY.
2015 Morris, M. J., Higano, C. S., Scher, H. I., Sweeney, C., Antonarakis, E. S., Shevrin, D. H., . . . Carrasquillo, J. A. (2015). Effects of radium-223 dichloride (Ra-223) with docetaxel (D) versus D on prostate-specific antigen (PSA) and bone alkaline phosphatase (bALP) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases (mets): A phase 1/2a clinical trial.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Orlando, FL: AMER SOC CLINICAL ONCOLOGY.
WoS12015 Van Allen, E. M., Kryukov, G., Bielski, C., Samocha, K., Fromer, M., Seepo, S., . . . Taplin, M. -E. (2015). Transgenerational genomic effect of chemotherapy exposure in testicular cancer survivors.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
2015 Sartor, A. O., Fernandez, D. C., Morris, M. J., Iagaru, A., Brown, A., Almeida, F., . . . Vogelzang, N. J. (2015). Prior and concurrent use of abiraterone and enzalutamide with Ra-223 in an expanded access setting.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Orlando, FL: AMER SOC CLINICAL ONCOLOGY.
WoS22015 Coulson, H., Loda, M., O'Donnell, E., Sweeney, C., & Hirsch, M. (2015). Targeted Next Generation Sequencing of Testicular Germ Cell Tumors. Poster session presented at the meeting of MODERN PATHOLOGY. SPRINGERNATURE. 2015 Williams, S. G., Davis, I. D., Sweeney, C., Stockler, M. R., Martin, A. J., Marchesin, V., . . . Nguyen, P. L. (2015). Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised prostate cancer: The ANZUP ENZARAD Trial (ANZUP 1303).. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
2015 McKay, R. R., Werner, L., Harshman, L. C., Bellmunt, J., Sweeney, C., Rosenberg, J. E., . . . Choueiri, T. K. (2015). A phase I study of buparlisib (BKM120) with bevacizumab (BEV) in patients (pts) with metastatic renal cell carcinoma (mRCC) progressing on prior vascular endothelial growth factor (VEGF) therapies.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
WoS62015 Curreri, S. A., Markt, S. C., Miller, R., O'Donnell, E., Bernard, B. D., Kamran, S. C., . . . Beard, C. (2015). Bilateral testicular germ cell tumors. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Orlando, FL: AMER SOC CLINICAL ONCOLOGY.
2015 Morris, M. J., Higano, C. S., Scher, H. I., Sweeney, C., Antonarakis, E. S., Shevrin, D. H., . . . Carrasquillo, J. A. (2015). Effects of radium-223 dichloride (Ra-223) with docetaxel (D) vs D on prostate-specific antigen (PSA) and bone alkaline phosphatase (bALP) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases (mets): A phase 1/2a clinical trial.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
WoS22015 Pal, S. K., Azad, A., Bhatia, S., Drabkin, H. A., Costello, B. A., Sarantopoulos, J., . . . Hutson, T. E. (2015). Association of baseline IL-8 and ferritin with clinical outcome with everolimus and BNC105P in the DisrupTOR-1 trial. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Orlando, FL: AMER SOC CLINICAL ONCOLOGY.
2015 Vogelzang, N. J., Fernandez, D. C., Morris, M. J., Iagaru, A., Brown, A., Almeida, F., . . . Sartor, A. O. (2015). Radium-223 dichloride (Ra-223) in US expanded access program (EAP).. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Orlando, FL: AMER SOC CLINICAL ONCOLOGY.
WoS42015 Bernard, B. D., Markt, S. C., Albiges, L., Miller, R., Beard, C., & Sweeney, C. (2015). Melanoma risk in men with testicular germ cell tumors in the United States. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
2015 Morris, M. J., Sartor, A. O., Vogelzang, N. J., Shore, N. D., Cislo, P., Bangerter, K., & Sweeney, C. (2015). Effect of radium-223 dichloride (Ra-223) on pain from US EAP.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Orlando, FL: AMER SOC CLINICAL ONCOLOGY.
WoS52015 Davis, I. D., Stockler, M. R., Martin, A. J., Marchesin, V., Deignan, O., McDermott, R., . . . Sweeney, C. (2015). Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: the ANZUP ENZAMET Trial (ANZUP 1304).. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
2015 Albiges, L., Xie, W., Chen, Y. -H., Boher, J. -M., Valenca, L. B., Bernard, B. D., . . . Sweeney, C. (2015). Disease burden and outcome in metastatic hormone sensitive prostate cancer (mHSPC).. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
2014 Cortazar, J. M., Howitt, B. E., O'Donnell, E., Sweeney, C., Ulbright, T., & Hirsch, M. S. (2014). Hilar Soft Tissue Involvement by Testicular Germ Cell Tumors Is Associated with Advanced Stage Indicators. Poster session presented at the meeting of LABORATORY INVESTIGATION. San Diego, CA: NATURE PUBLISHING GROUP. 2014 Williams, S., Davis, I., Sweeney, C., Stockler, M., Martin, A., Long, A., . . . Nguyen, P. (2014). RANDOMISED PHASE 3 TRIAL OF ENZALUTAMIDE IN ANDROGEN DEPRIVATION THERAPY WITH RADIATION THERAPY FOR HIGH RISK, CLINICALLY LOCALISED, PROSTATE CANCER: THE ANZUP ENZARAD STUDY. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY-BLACKWELL. 2014 Sweeney, C., Gray, K. P., Harshman, L. C., Elfiky, A., Choueiri, T. K., Pomerantz, M., . . . Kantoff, P. W. (2014). Phase 1 dose-finding study of cabozantinib (cabo) plus abiraterone (abi) combination therapy in castration resistant prostate cancer (CRPC): An investigator-sponsored study.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.
WoS12014 Sweeney, C., Chen, Y., Carducci, M., Liu, G., Jarrard, D., Eisenberger, M., . . . Dipaola, R. (2014). CHEMOHORMONAL THERAPY VERSUS HORMONAL THERAPY FOR HORMONE NAIVE HIGH VOLUME NEWLY METASTATIC PROSTATE CANCER (PRCA): ECOG LED PHASE III RANDOMIZED TRIAL. Poster session presented at the meeting of ANNALS OF ONCOLOGY. Madrid, SPAIN: OXFORD UNIV PRESS.
WoS22014 Kaymakcalan, M. D., Stuver, S., Sweeney, C., Choueiri, T. K., & Elfiky, A. (2014). Patient risk factors and pegfilgrastim use in cabazitaxel-treated prostate cancer pateints in an academic setting.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
WoS12014 Mahal, B. A., Aizer, A. A., Ziehr, D. R., Hyatt, A. S., Choueiri, T. K., Jim, H. C., . . . Nguyen, P. L. (2014). The Impact of Race on Prostate-Cancer Specific Mortality Among Men With Low-Risk Disease: Potential Implications for Active Surveillance. Poster session presented at the meeting of INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. San Francisco, CA: ELSEVIER SCIENCE INC.
2014 Sweeney, C., Chen, Y. -H., Carducci, M. A., Liu, G., Jarrard, D. F., Eisenberger, M. A., . . . DiPaola, R. S. (2014). Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. 2014 Mahal, B. A., Aizer, A. A., Ziehr, D. R., Hyatt, A. S., Sammon, J. D., Schmid, M., . . . Nguyen, P. L. (2014). Racial Disparities in the Management of African American Men With Intermediate- to High-Risk Prostate Cancer. Poster session presented at the meeting of INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. San Francisco, CA: ELSEVIER SCIENCE INC.
WoS12014 Sweeney, C., Chen, Y. -H., Carducci, M. A., Liu, G., Jarrard, D. F., Eisenberger, M. A., . . . DiPaola, R. S. (2014). Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrca): An ECOG-led phase III randomized trial. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. 2014 Mahal, B. A., Ziehr, D. R., Hyatt, A., Aizer, A. A., Sammon, J. D., Schmid, M., . . . Paul, L. N. (2014). The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.
2014 Cortazar, J. M., Howitt, B. E., O'Donnell, E., Sweeney, C., Ulbright, T., & Hirsch, M. S. (2014). Hilar Soft Tissue Involvement by Testicular Germ Cell Tumors Is Associated with Advanced Stage Indicators. Poster session presented at the meeting of MODERN PATHOLOGY. San Diego, CA: NATURE PUBLISHING GROUP. 2014 Zukotynski, K., Kim, C., Gerbaudo, V., Hainer, J., Van Den Abbeele, A., Seltzer, S., & Sweeney, C. (2014). Prognostic value of baseline evaluation of FDG and NaF PET/CT in castrate-resistant prostate cancer (CRPC): Early results from a prospective phase 1 trial. Poster session presented at the meeting of JOURNAL OF NUCLEAR MEDICINE. St Louis, MO: SOC NUCLEAR MEDICINE INC. 2014 Howard, S. A. H., Gray, K. P., O'Donnell, E., Fennessy, F. M., Beard, C., & Sweeney, C. (2014). Craniocaudal retroperitoneal node length as a risk factor for relapse from clinical stage I testicular germ cell tumor. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
2014 O'Donnell, E., Feldman, H., Lago-Hernandez, C., Hirsch, M. S., Beard, C., Van Allen, E. M., . . . Sweeney, C. (2014). Tumor genomic mutation profiling of germ cell tumors using "Profile".. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.
2014 Davis, I., Stockler, M., Martin, A., Long, A., Yip, S., Coskinas, X., & Sweeney, C. (2014). RANDOMISED PHASE 3 TRIAL OF ENZALUTAMIDE IN FIRST LINE ANDROGEN DEPRIVATION THERAPY FOR METASTATIC PROSTATE CANCER: THE ANZUP ENZAMET STUDY. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY-BLACKWELL. 2013 Choueiri, T. K., Jacobus, S. J., Qu, A. Q., Sweeney, C., Appleman, L. J., Tretter, C. P. G., . . . Ross, R. W. (2013). A phase II multicenter study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy with pegfilgrastim support in patients (pts) muscle-invasive urothelial cancer (MIUC): Safety, pathologic, radiologic, and molecular correlates. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Orlando, FL: AMER SOC CLINICAL ONCOLOGY.
2013 Milowsky, M. I., Dittrich, C., Martinez, I. D., Jagdev, S., Millard, F. E., Sweeney, C., . . . Sternberg, C. N. (2013). Final results of a multicenter, open-label phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated <i>FGFR3</i>. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Orlando, FL: AMER SOC CLINICAL ONCOLOGY.
WoS192013 Hutson, T. E., Dang, L. H., Lauer, R. C., Starodub, A., Hauke, R. J., Galsky, M. D., . . . Sarantopoulos, J. (2013). Updated phase I results of a phase I/II trial of BNC105P with everolimus in patients with metastatic renal cell carcinoma (mRCC). Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Orlando, FL: AMER SOC CLINICAL ONCOLOGY.
2013 Elfiky, A., Kaymakcalan, M., Stuver, S., Sweeney, C., Jacobson, J. O., & Weingart, S. (2013). Developing and promoting evidence-based use of granulocyte colony stimulating factors (GCSF) in the palliative chemotherapy setting. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. San Diego, CA: AMER SOC CLINICAL ONCOLOGY.
2013 O'Donnell, E., Gray, K. P., Ravi, P., & Sweeney, C. (2013). A meta-analysis of patient outcomes with subcentimeter disease after chemotherapy for metastatic nonseminomatous germ cell tumor (NSGCT). Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Orlando, FL: AMER SOC CLINICAL ONCOLOGY.
WoS12013 Sarantopoulos, J., Dang, L. H., Lauer, R. C., Starodub, A., Hauke, R. J., Galsky, M. D., . . . Hutson, T. E. (2013). A phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC) patients: Updated phase I results of the Disruptor-1 trial. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.
WoS12013 Scher, H. I., Smith, M. R., Sweeney, C., Corn, P. G., Logothetis, C., Vogelzang, N. J., . . . Basch, E. M. (2013). An exploratory analysis of bone scan lesion area (BSLA), circulating tumor cell (CTC) change, pain reduction, and overall survival (OS) in patients (pts) with castration-resistant prostate cancer (CRPC) treated with cabozantinib (cabo): Updated results of a phase II nonrandomized expansion (NRE) cohort.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. 2013 Yoo, S. M., Werner, L., Nakabayashi, M., Sweeney, C., Hirsch, M. S., Kantoff, P. W., & Pomerantz, M. M. (2013). Clinicopathologic features and clinical outcomes associated with Gleason upgrading from biopsy to radical prostatectomy. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. 2013 O'Donnell, E., Gray, K. P., Hirsch, M. S., Ravi, P., Beard, C., & Sweeney, C. (2013). A 10-year retrospective review of germ cell tumors not cured with cisplatin-based chemotherapy. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Orlando, FL: AMER SOC CLINICAL ONCOLOGY.
2013 Morris, M. J., Hammers, H. J., Sweeney, C., Antonarakis, E. S., Cho, S. Y., Pandit-Taskar, N., . . . Carrasquillo, J. A. (2013). Safety of radium-223 dichloride (Ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC): A phase I Prostate Cancer Clinical Trials Consortium Study. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.
WoS92013 Chi, K. N., Sweeney, C., Jacobs, C., Stewart, P. S., & Hahn, N. M. (2013). The Pacific trial: A randomized phase II study of OGX-427 in men with metastatic castration-resistant prostate cancer (mCRPC) and PSA progression while receiving abiraterone acetate (AA).. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.
WoS12013 Strock, J., Gray, K. P., Nakabayashi, M., Evan, C., O'Donnell, E., Pomerantz, M., . . . Sweeney, C. (2013). Characterization of patients who present with de novo metastatic prostate cancer: Single-institution database analysis. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Orlando, FL: AMER SOC CLINICAL ONCOLOGY.
WoS32013 O'Donnell, E., Gray, K. P., Hirsch, M. S., Kantoff, P. W., Beard, C., & Sweeney, C. (2013). Smoking history and disease outcomes in patients with malignant germ cell tumors.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.
-
Current Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2023 Co-Supervisor Identifying novel metabolic drivers of lethal prostate cancer Doctor of Philosophy Doctorate Full Time Dr Michael Adam Cilento 2023 Co-Supervisor Defining and describing different clinical phenotypes of local and metastatic prostate cancer using Prostate Specific Membrane Antigen PET Doctor of Philosophy Doctorate Part Time Dr Mrunal Devendra Hiwase
Connect With Me
External Profiles
